



A

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

UTILITY PATENT APPLICATION TRANSMITTAL FORM
(only for new nonprovisional applications under 37 CFR 1.53(b))



ASSISTANT COMMISSIONER FOR PATENTS
Washington, D.C. 20231
BOX: PATENT APPLICATION

SIR:

Transmitted herewith for filing is the patent application (including Specification, Claims, Sequence Listing (if applicable) and Abstract, 91 pages) of:

Inventor(s): **David G. Hangauer, Jr., Thomas H. Marsilje, and Karen L. Milkiewicz**

For : **A NOVEL METHOD FOR DESIGNING PROTEIN KINASE INHIBITORS**

***If a CONTINUING APPLICATION, please mark where appropriate and supply the requisite information below and in a preliminary amendment:*

☐ continuation ☐ divisional ☐ Continuation-In-Part (CIP)
of prior application Serial No. _____

Prior application information: Examiner :
Art Unit :

Enclosed are:

- ☒ 15 sheets of informal drawings.
- ☐ **Signed** Combined Declaration and Power of Attorney (_____ pages).
- ☐ **Copy** of **signed** Combined Declaration and Power of Attorney (_____ pages) from a prior application (1.63(d) (for continuation/divisional).
- ☐ **Signed** statement deleting inventor(s) named in prior application (_____ pages) (1.63(d)(2) and 1.33(b)).
- ☐ **Incorporation By Reference:** The entire disclosure of the prior application, from which a **copy** of the oath or declaration is supplied herewith, is considered as being part of the disclosure of the enclosed application and is hereby incorporated by reference therein.
- ☐ Assignment (_____ pages) of the invention to _____.
- ☐ Assignment Transmittal Letter.
- ☐ Certified copy of a foreign priority document.
- ☐ Associate power of attorney.
- ☐ Verified statement to establish small entity status (_____ pages) (newly signed or copy filed in prior application).

- ☐ Preliminary Amendment (_____ pages).
- ☐ Information Disclosure Statement, form PTO-1449 (_____ pages) and _____ references.
- ☒ **UNSIGNED** Combined Declaration and Power of Attorney (2 pages).
- ☐ Statement in Accordance with 37 CFR § 1.821(f) and computer readable 3.5" Diskette.
- ☒ A self-addressed, prepaid postcard acknowledging receipt.
- ☐ Other:

The Filing fee has been calculated as shown below:


	(Col. 1)	(Col. 2)	SMALL ENTITY			LARGE ENTITY	
FOR:	NO. FILED	NO. EXTRA	RATE	FEE	OR	RATE	FEE
BASIC FEE	XXXXXXXX	XXXXXXXX	XXXX	\$380	OR	XXXX	\$760
TOTAL CLAIMS	69 - 20 =	49	x 9 =	\$441	OR	x 18 =	\$
INDEP CLAIMS	6 - 3 =	3	x 39 =	\$117	OR	x 78 =	\$
<input type="checkbox"/> MULTIPLE DEPENDENT CLAIM PRESENTED			x 130 =	\$	OR	x 260 =	\$
*If the Total Claims are less than 20 and Indep. Claims are less than 3, enter "0" in Col. 2			TOTAL	\$938	OR	TOTAL	\$

☒ A check in the amount of **\$938.00** to cover the filing fee is enclosed.

☒ Address all future communications to:

Michael L. Goldman
NIXON PEABODY LLP
Clinton Square, P.O. Box 1051
Rochester, New York 14603

Date: 1/13/00


Dennis M. Connolly
Registration No. 40,964

NIXON PEABODY LLP
Clinton Square, P.O. Box 1051
Rochester, New York 14603
Telephone: (716) 263-1741
Facsimile: (716) 263-1600

A NOVEL METHOD FOR DESIGNING PROTEIN KINASE INHIBITORS

The present application claims the benefit of U.S. Provisional Patent
5 Application Serial No. 60/115,643, filed January 13, 1999.

BACKGROUND OF THE INVENTION

Protein kinases are a large class of enzymes which catalyze the transfer of the
10 γ -phosphate from ATP to the hydroxyl group on the side chain of Ser/Thr or Tyr in
proteins and peptides and are intimately involved in the control of various important
cell functions, perhaps most notably: signal transduction, differentiation and
proliferation. There are estimated to be about 2,000 distinct protein kinases in the
human body (Hunter, 1987, 1994, Hanks & Hunter, 1995), and although each of these
15 phosphorylate particular protein/peptide substrates, they all bind the same second
substrate ATP in a highly conserved pocket.

Inhibitors of various known protein kinases could have a variety of therapeutic
applications provided sufficient selectivity, and acceptable *in vivo* pharmacological
properties, can be incorporated into such inhibitors (Levitzki, 1996a). Perhaps the
20 most promising potential therapeutic use for protein kinase inhibitors is as anti-cancer
agents. This potential application for protein tyrosine kinase ("PTK") inhibitors has
been highlighted in many recent reviews (e.g. Lawrence & Hiu, 1998, Kolibaba &
Druker, 1997, Showalter & Kraker, 1997, Patrick & Heimbrosk, 1996, Groundwater
et al., 1996, Levitzki, 1995). The foundation for this application is based partly upon
25 the fact that about 50% of the known oncogene products are PTKs and their kinase
activity has been shown to lead to cell transformation (Yamamoto, 1993).

The PTKs can be classified into two categories (Courtneidge, 1994), the
membrane receptor PTKs (e.g. growth factor receptor PTKs) and the non-receptor
PTKs (e.g. the src family of proto-oncogene products). There are at least 9 members
30 of the src family of non-receptor PTK's with pp60^{c-src} (hereafter referred to simply as
"src") being the prototype PTK of the family wherein the ca. 300 amino acid catalytic
domains are highly conserved (Rudd et al., 1993, Courtneidge, 1994). The
hyperactivation of src has been reported in a number of human cancers, including

those of the colon (Mao et al., 1997, Talamonti et al., 1993), breast (Luttrell et al., 1994), lung (Mazurenko et al., 1992), bladder (Fanning et al., 1992) and skin (Barnekow et al., 1987) as well as in gastric cancer (Takeshima et al., 1991), hairy cell leukemia (Lynch et al., 1993) and neuroblastoma (Bjelfman et al., 1990).

- 5 Overstimulated cell proliferation signals from transmembrane receptors (e.g. EGFR and p185HER2/Neu) to the cell interior also appears to pass through src (Mao et al., 1997, Parsons & Parsons, 1997, Bjorge et al., 1996, Taylor & Shalloway, 1996). Consequently, it has recently been proposed that src is a universal target for cancer therapy (Levitzki, 1996) because its' hyperactivation (without mutation) is involved in
- 10 tumor initiation, progression and metastasis for many important human tumor types.

In view of the large, and growing, potential for inhibitors of various protein kinases, a variety of approaches to obtaining useful inhibitors is needed. The status of the discovery of PTK inhibitors (Lawrence & Niu, 1988, Showalter & Kraker, 1997, Patrick & Heimbrook, 1996, Groundwater et al., 1996, Budde et al., 1995, Levitzki &

15 Gazit, 1995) has been extensively reviewed. Random screening efforts have been successful in identifying non-peptide protein kinase inhibitors but the vast majority of these bind in the highly conserved ATP binding site. A notable recent example of such non-peptide, ATP-competitive, inhibitors are the 4-anilinoquinazolines, and analogs, which were shown to be effective against the epidermal growth factor

20 receptor PTK (EGFR TK) (e.g. Rewcastle et al., 1996). Although this class of inhibitors was reported to be selective for the EGFR PTK vs. six other PTKs (including src, Fry et al., 1994) it is unknown what their effect is on most of the remaining 2,000 protein kinases that all bind ATP as well as a large number of other ATP, ADP, GTP, GDP, etc. utilizing proteins in the body. Therefore, potential side

25 effects from PTK inhibitor drugs that mimic ATP, which might only be discovered after expensive animal toxicity studies or human clinical trials, are still a serious concern. Also, although this class of compounds was a nice discovery and is undergoing further exploration, they do not provide a rational and general solution to obtaining non-peptide inhibitors for any desired PTK, e.g. in this case src. The risk of

30 insufficient specificity *in vivo* with ATP-competitive PTK inhibitors has also been noted by others, along with the inherent three order of magnitude reduction in potency these inhibitors display when competing with the mM levels of intracellular ATP

rather than the μM levels used in the isolated enzyme assays (e.g. see Lawrence & Niu, 1998, Hanke et al., 1996, Kelloff et al., 1996).

An older, and more extensively studied, class of non-peptide PTK inhibitors is erbstatin and the related tyrphostins (see reviews). This class of inhibitors are active
5 against the receptor PTKs and their mode of inhibition is complex but does not appear to involve binding in the peptide substrate specificity site regions of the active site (Hsu et al., 1992, Posner et al., 1994). Furthermore, they are inactive against the isolated PTK when the *unnatural* assay metal Mn^{2+} is replaced with the *natural* Mg^{2+} (Hsu et al., 1992), are chemically unstable (Budde et al., 1995, Ramdas et al.,
10 1995 & 1994), and are known to be cytotoxic to normal and neoplastic cells by crosslinking proteins (Stanwell et al., 1995 & 1996) as well as inhibit cell growth by disrupting mitochondria rather than PTK inhibition (Burger et al., 1995).

An important contribution to the protein kinase field has been the x-ray structural work with the serine kinase cAMP-dependent protein kinase ("PKA")
15 bound to the 20-residue peptide derived from the heat stable inhibitor protein, PKI(5-24), and Mg_2ATP (Taylor et al., 1993). This structural work is particularly valuable because PKA is considered to be a prototype for the entire family of protein kinases since they have evolved from a single ancestral protein kinase. Sequence alignments of PKA with other serine and tyrosine kinases have identified a conserved catalytic
20 core of about 260 residues and 11 highly conserved residues within this core (Taylor et al., 1993). Two highly conserved residues of particular note for the work proposed herein are the general base Asp-166 which is proposed to interact with the substrate OH and the positively charged residue, Lys-168 for serine kinases and an Arg for
25 tyrosine kinases (Knighton et al., 1993), which is proposed to interact with the γ -phosphate of ATP to help catalyze transfer of this phosphate. Two additional important PKA crystal structures have been reported (Madhusudan et al., 1994), one for the ternary PKA:ADP:PKI(5-24) complex wherein the PKI Ala 21 has been replaced with Ser (thereby becoming a substrate), and one for the binary PKA:PKI(5-24) complex wherein the PKI Ala 21 has been replaced with
30 phosphoserine (an end product inhibitor). The ternary complex shows the serine OH donating a H-bond to Asp-166 and accepting a H-bond from the side chain of Lys 168. The binary complex shows the phosphate group of phosphoserine forming a salt

bridge with the Lys-168 side chain and within H-bonding distance of the Asp-166 carboxyl group. These structures support the earlier proposed roles for Asp-166 and Lys-168 in the catalytic mechanism.

The x-ray structures of PKA show that the enzyme consists of two lobes wherein the smaller lobe binds ATP and the larger lobe the peptide substrate. Catalysis occurs at the cleft between the lobes. The crystallographic and solution structural studies with PKA have indicated that the enzyme undergoes major conformational changes from an "open" form to the "closed" catalytically active form as it binds the substrates (Cox et al., 1994). These conformational changes are presumed to involve the closing of the cleft between the two lobes as the substrates bind bringing the γ -phosphate of ATP and the Ser OH in closer proximity for direct transfer of the phosphate.

However, the inhibitors of protein kinases still lack the specificity and potency desired for therapeutic use. Due to the key roles played by protein kinases in a number of different diseases, including cancer, psoriasis, arthrosclerosis, and their role in regulating immune system activity, inhibitors of specific protein kinases are needed. The present invention provides a novel approach for designing protein kinase inhibitors, which are more potent as well as being more specific for the targeted pathways.


SUMMARY OF THE INVENTION

The present invention provides a method for identifying inhibitors of protein kinases. A first module having a one or more functional groups for binding to catalytic residues of the protein kinase is combined with a second module which provides a non-peptide scaffold. Combinations of the first and second modules which inhibit protein kinase activity are selected.

The present invention also provides a method of inhibiting a protein kinase. The protein kinase is contacted by a compound comprising a first module having a functionality for binding to catalytic residues of the protein kinase and a second module which provides a non-peptide scaffold. The combination of the first and second modules inhibits the protein kinase activity.

In a further embodiment, the invention provides a non-peptide protein tyrosine kinase inhibitor having the formula:

5




10

wherein wherein R1 is H or OH, R2 is H or OH, R3 is OH or H, and R4 is CH₃, CH₂(CH₃)R, or CH₂(CH₃)S, R5 is OCH₃, H, or OH, R6 is OCH₃, F, H, or OH, and R7 is OCH₃, H, OH, CO₂H, CO₂CH₃, CH₂CO₂H, or CH₂CO₂CH₃.

The present invention also provides a non-peptide protein tyrosine kinase inhibitor having the formula:

15



20

wherein R1 is OH or H, R2 is OH or H, R3 is OH or H, R4 is OH or H, R5 is OH, OMe, or H, R6 is OH, OMe, or H, R7 is OH, OMe, or H, and X is 0 or 1.

25

In yet another embodiment, the present invention provides a method of treating a condition, responsive to a protein kinase inhibitor, in a patient. A protein kinase inhibitor is administered to a patient. The protein kinase inhibitor has a first module having a functionality for binding to catalytic residues of the protein kinase and a second module which provides a non-peptide scaffold. The combination of the first and second modules inhibits protein kinase activity in the patient.

30

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 depicts the modular strategy for developing non-peptide protein kinase inhibitors. Step 1 utilizes one or more first modules ("M₁'s") to identify

promising non-peptide scaffolds. Step 2 enhances the potency by adding specificity elements. During this step the scaffolds are validated. Whether the inhibitor is non-ATP competitive can also be determined. In step 3, the potency and selectivity are further enhanced using combinatorial libraries to optimize M₁ and specificity elements.

Figure 2 provides a depiction of the x-ray structure of (PKA):Mg₂ATP:pseudosubstrate inhibitor.

Figure 3 provides a general module M₁ design features for binding to the conserved protein kinase catalytic region.

Figure 4 shows that the boronic acid “inhibitors” **21** and **22** were shown to be substrates for PKA.

Figure 5 demonstrates the binding interactions of src substrate Ac-Ile-Tyr-Glu-Phe-NH₂ in model src active site.

Figure 6 shows the design of naphthalene-based src inhibitor scaffolds.

Figure 7 shows the design of isoquinoline and indole-based src inhibitor scaffolds.

Figure 8 provides an example of the chemistry used to prepare the naphthalene inhibitors, which is described in Marsilje 2000. A boronic acid functionality can be put in place of a M₁ hydroxyl groups in the src inhibitors from Table 5 using the Pd (0)-catalyzed cross-coupling methodology was used wherein either an aryl triflate (Ishiyama et al, 1997) or an aryl halide (Ishiyama, 1995) can be coupled with the commercially available pinacol ester of diboron.

Figure 9 shows a synthetic scheme that can be followed, in order to attach hydrophobic S₂ selectivity elements to the naphthalene scaffold.

Figure 10 shows successful model reactions with naphthalene chemistry, which can be converted to the solid phase in preparation for synthesizing combinatorial libraries of this scaffold in a 96-well plate format. The chemistry has been carried out on the less active naphthalene regioisomer represented by **44** because this compound is readily obtained from commercially available 3,5-dihydroxy-2-naphthoic acid as describe in Marsilje 2000.

Figure 11 provides a possible strategy for modifying the naphthalene scaffold in combinatorial libraries.

Figure 12 shows the conversion of the triflate functionality formed in reaction 2 from intermediate **69** (Figure 11) to an amine (Wolfe et al, 1997) and then a series of amides or other amine derivatives.

Figure 13 Following the modeling procedure described above, a the series of hydroxy-containing analogs of the boronic acid M₁ group shown in Figure 13 were modeled in the src and IRTK (insulin receptor protein tyrosine kinase) active sites and found the illustrated interactions/binding modes as some of the interesting possibilities.

Figure 14 shows results from testing of the non-peptide src inhibitor **43**-meta (Table V) in the LA25 and NRK cell lines.

Figure 15A shows a comparison of taxol and doxorubicin (they were more effective than etoposide & cisplatin in this tumor cell culture) with the three Src inhibitors mentioned above utilizing ovarian tumor cells from tumor N015. Figure 15B shows the results from tests of the src inhibitors for inhibition of normal human fibroblast cell growth. No inhibition of normal cell growth (both subconfluent and confluent; some enhanced growth was observed instead) was found, indicating that these inhibitors are not toxic to normal cells even at a 10-fold higher concentration. Figure 15 C provides the structures of the src inhibitors TOM 2-32, TOM 2-47, and KLM 2-31.

DETAILED DESCRIPTION OF THE INVENTION

The present invention provides a method for identifying inhibitors of protein kinases. The general modular strategy for the development of non-peptide PTK inhibitors is outlined in Figure 1. Basically, a first module having a one or more functional groups for binding to catalytic residues of the protein kinase is combined with a second module which provides a non-peptide scaffold. Combinations of the first and second modules which inhibit protein kinase activity are then selected. Step 1 begins with protein kinase inhibitor information which was already generated, i.e. pentapeptide scaffolds which bind in the substrate specificity sites of PKA or src have already been used to position various rationally designed functional groups (i.e. module "M₁" or "first module") to interact with the conserved catalytic residues, MgATP or MgADP. A selection of preferred functional groups have now been

identified in this fashion to serve as the initial M_1 module for Step 1. These M_1 functional groups have been utilized to identify promising non-peptide scaffolds for src inhibitors in Step 1. It was anticipated that these bare non-peptide scaffolds, with only an M_1 appendage, would have low binding affinity and be relatively non-selective among the PTKs. A lack of selectivity at the level of Step 1 is viewed as an advantage for the development of a general strategy which can be reapplied to additional PTKs. Therefore the suite of non-peptide scaffolds identified in Step 1 can be recycled for use against additional PTKs by rescreening them and carrying the better ones through Steps 2 and 3, all using the new PTK target. The potency of these bare scaffolds from Step 1 may be increased enough by the attachment of one or two initial specificity elements (S_n) to allow for the validation of the scaffold as non-ATP competitive and amenable to further potency enhancements using combinatorial chemistry in a rationally guided fashion. Promising src non-peptide M_2 (second module) scaffolds identified in Step 1 have undergone Step 2 and displayed a one to two order-of-magnitude increase in potency against src as well as non-competitive binding relative to ATP.

Validation of the scaffolds at the level of Step 2 before undertaking the resource intensive combinatorial library synthesis and testing of Step 3 is important for three reasons: 1) To develop the chemistry for appending the specificity element (S_n) side chains. 2) To determine that these inhibitors are not ATP-competitive. 3) To determine that the potency is responding to the side chain S_n properties and attachment points as would be expected based upon the working model for the src:inhibitor complex (this provides some confidence that rationally guided choices can be made for the ranges of individual selectivity elements S_n to include in the focused libraries of Step 3).

It is in Step 3 that high potency and specificity for a particular PTK is anticipated because numerous combinations of M_1 functional groups (and close analogs M_1') with selectivity elements (S_n) will be evaluated experimentally via combinatorial chemistry and high-throughput screening. Potency and selectivity may be further increased if necessary by appending additional specificity elements (see optional S_n 's in Figure 1). One of the selected src inhibitor scaffolds from Step 2 has already been attached to a solid phase resin and is currently being developed into a combinatorial library following Step 3.

In each of the Steps 1-3, molecular modeling studies with the IRTK:peptide:AMP-PNP crystal structure, the model of the src:peptide complex and the models for the src complex with the individual families of inhibitors based upon a particular scaffold will be used as qualitative guides. These modeling studies have
5 been remarkably helpful thus far in guiding the inhibitor design efforts as detailed later. Combining structure-based design and combinatorial chemistry technologies in this fashion provides a synergy wherein the major individual deficiencies of these technologies used in isolation are addressed by the strengths of the other. The major deficiency of structure-based design is the difficulty in quantitatively predicting
10 ligand binding affinities, which is particularly challenging due to the complex effects of solvation and entropy (Ajay & Murcko, 1995). The major strength of structure-based design is its' capability to predict what types of molecules are likely to be good ligands. Structure-based design can determine the rough boundaries (proteins have some flexibility which need to be taken into account) for molecular size and shape as
15 well as indicate where hydrophobic, H-bonding and ionic interactions are likely to occur. On the other hand, the major deficiency of combinatorial chemistry is that "molecular space" for drug-sized molecules (i.e. MW ca. 500 or less) is so large that one could not hope to sample all of this molecular space with a high density of coverage in a reasonable sized combinatorial library. A recent estimate (Bohacek et
20 al., 1996) of the number of possible compounds containing up to 30 atoms chosen only from carbon, nitrogen, oxygen and sulfur (in addition to H's) is 10^{60} compounds. This is in the molecular weight range of typical drug molecules and still does not include additional diversity provided by other atoms, e.g. halogens. Consequently, additional constraints need to be used to identify regions of molecular space wherein
25 particular drug candidates are likely to be located. Structure-based design can drastically reduce the volume of molecular space to be explored by identifying the types of molecules which have a higher probability of being good ligands. The inability to quantitatively predict which of these "focused" combinatorial library members will in fact be the tightest binding ligands (i.e. the quantitation problem) is
30 then resolved by employing an efficient combinatorial synthesis and high-throughput testing of the library.

In the earlier peptide based serine and tyrosine kinase inhibitor design efforts PKA was used as a convenient qualitative model for designing the protein kinase

inhibitor module M_1 for interaction with the conserved catalytic residues. There is much more structural and kinetic information available for PKA than any other protein kinase.

The crystal structure of PKA complexed with Mg_2ATP and a pseudosubstrate (i.e. OH replaced with H) peptide inhibitor (PKI 5-24 amide) has been solved (Zheng et al., 1993) and the active site interactions near the P 0 Ala of this inhibitor are shown in Figure 2.

This crystal structure shows Mg_2ATP bound to the small lobe of PKA and a 20-residue pseudosubstrate peptide inhibitor bound to the large lobe with the overall conformation of the enzyme in the closed (i.e. the two lobes are touching) and activated state. The distances between the P 0 Ala side chain carbon and the nearby heavy atoms in the complex are shown in \AA in Figure 1. These distances show that the Ala side chain is within van der Waals contact distance of the surrounding atoms and indicates that there is little space for appending bulky M_1 functional groups to the Ala side chain. However, PKA is a flexible enzyme with open, closed and intermediate conformations (Cox et al., 1994) and these more open conformations would result in a retraction back of the ATP γ -phosphate from the inhibitor Ala thereby creating a binding cavity for appended M_1 functional groups. Furthermore, PKA binds $MgADP$ with the same affinity as $MgATP$ (Whitehouse et al., 1983) and the ratio of ATP/ADP in cells is typically 10/1 (Alberts, et al. 1994). Therefore, at equilibrium, ca. 10% of the cellular protein kinase is in the $MgADP$ bound state and this form of the enzyme can also be targeted with an inhibitor to drain all of the enzyme from the catalytic cycle into a PKA: $MgADP$:inhibitor inactive complex.

Since the PKA catalytic residues Asp-166 and Lys-168 are completely conserved in all serine kinases, and the tyrosine kinases only differ by the substitution of Arg for Lys-168 (Taylor et al., 1993), this region of the active site was chosen, along with the adjoining $MgATP$ or $MgADP$, to target a selection of inhibitor functional groups which could serve as M_1 and be broadly useful for developing inhibitors for the entire protein kinase family. By targeting M_1 to the region of the active site adjacent to the nucleotide, an orientation point is provided for the non-peptide inhibitors which can extend into the peptide binding specificity sites without always competing with ATP/ADP binding.

A selection of functional groups which could be utilized as M_1 was identified first because, although this region of the active site is very highly conserved, it was expected that each particular protein kinase will still display some differing preferences across this selection due to small variations in the active site conformations and adjoining residues. Furthermore, the rank order preference among this selection of M_1 's may change somewhat as the M_1 module is appended to different non-peptide scaffolds. This expectation is based upon the potential for each non-peptide scaffold to bind in somewhat different orientations with each individual protein kinase and with each particular set of selectivity element (S_n) side chains. Pentapeptide scaffolds were chosen for the initial screening of functional groups for M_1 because the binding orientation of these larger peptide scaffolds is likely to be very consistent and predictable (i.e. closely resembling that observed by x-ray) throughout the series and could be more confidently assumed to position each tested M_1 functionality adjacent to the conserved catalytic residues as intended. Consequently, the goal of this earlier peptide-based work was to identify a collection of M_1 functional groups which can be used, not only for the initial screening of non-peptide scaffolds (Step 1), but also as an initial set of M_1 side chains which can be further expanded via close analogs and thereby optimized simultaneously with the other side chains in the final non-peptide combinatorial libraries (Step 3).

In order to model the candidate M_1 functional groups in this conserved catalytic region of the PKA active site, they were built onto the P 0 Ala position in the PKA ternary structure using the SYBYL molecular modeling package (Tripos) on a Silicone Graphics workstation as indicated in Figure 3.

A crystal structure of PKA with MgATP and an inhibitor bound in a more "open" conformation was not available, so initial modeling studies were carried out on the MgADP bound form of PKA derived from the ternary complex illustrated in Figure 2 by simply deleting the ATP γ -phosphate. Initial modeling studies were used to provide qualitative guidance for identifying interesting potential M_1 functional groups for the protein kinase family before synthesis and testing. The most advanced computational algorithms for quantitatively predicting the free energy of binding, such as Free Energy Perturbation methods, are computationally intensive methods which are not practical at this point in time for routine use by the non-specialist. Even the most advanced methods can be inaccurate due to difficulties in sampling,

inadequacies in the molecular mechanics force fields/parameters, and an incomplete understanding of electrostatics in water (Ajay & Murcko, 1995). Less rigorous (and easier to use) computational methods tend to be unreliable in making quantitative predictions of binding affinities, especially when dealing with multiple polar and ionic interactions such as those involved in M₁ binding.

In order to allow molecular mechanics calculations to be done with the Silicone Graphics workstation in a reasonable amount of time, two layers of residues were carved out from the PKA ternary structure which are surrounding the PKA active site, along with the peptide inhibitor and Mg₂ADP. The M₁ functional groups were then appended to the P 0 Ala side chain and the entire PKA active site:Mg₂ADP:modified peptide inhibitor complex was then subjected to 300 iterations of molecular mechanics minimization using the Tripos force field with a distance dependent dielectric constant after assigning appropriate formal charges and calculating Gasteiger Marsili point charges using SYBYL. Setting the maximum number of iterations at 300 was sufficient to remove any serious strain in the complexes and yet not allow the overall structure to “drift” significantly from the starting x-ray structure if convergence is not reached. These minimized complexes were then visually evaluated to determine if the appended individual M₁ functional groups were able to engage in favorable interactions with the conserved catalytic residues and/or Mg₂ADP. This visual evaluation involved, among other standard interaction evaluations, measuring atom-atom distances to determine if hydrogen bonds and ionic interactions were being favorably formed.

Favorable intermolecular interactions between an individual M₁ functionality and the conserved catalytic residues or Mg₂ADP does not necessarily mean enhanced binding affinity will be observed for the new inhibitor. Unfavorable desolvation of both the polar M₁ functionality and the polar PKA active site residues (as well as complex entropy effects) are not included in this analysis and may reduce the net binding affinity to the point that the modified inhibitor may even be less potent than the corresponding P 0 Ala inhibitor, even though the appended M₁ functionality *is* interacting with the conserved catalytic residues and/or MgADP (or MgATP) as intended. Even in cases where this desolvation penalty results in no net increase in binding affinity, these M₁ functional groups are still useful as an orienting groups for correctly positioning the non-peptide inhibitor analogs in the protein kinase active

site. Positioning these polar functional groups elsewhere within the active site (assuming they are tethered so as not to be able to extend into bulk solvent while the scaffold is favorably bound in the active site) is likely to result in a reduced binding affinity because they were specifically designed and selected based upon their demonstrated ability (while appropriately tethered to pentapeptide scaffolds) to be accepted adjacent to the conserved catalytic residues and MgADP/MgATP. If a particular M₁ functionality does not correctly position a non-peptide scaffold in Step 1 then attempts to improve the potency by rationally appending initial specificity elements in Step 2 would likely fail.

None of the literature protein kinase assay procedures contain added ADP. A typical PKA literature assay procedure (Glass et al., 1989) was modified by adding 10% as much ADP as the ATP concentration used to reflect the natural 1/10 ratio in the cell. This protein kinase assay is hereinafter referred to as the "Literature Mimetic" assay. It has been used for PKA as well as the src. An examination of the literature, and commercially available protein kinase assays, showed that there is poor consistency from lab to lab and company to company and that all of these assays use physical chemical conditions which differ considerably from those known to exist inside cells. Since inhibition of intracellular protein kinases is the ultimate goal for drug discovery, new protein kinase assays have been developed which come much closer to mimicking the overall cytosolic physical chemical conditions known to exist inside cells. The development of these "Cellular Mimetic" protein kinase assays, is described herein, along with a novel method for determining which form of a protein kinase a given inhibitor binds best to (the STAIRe method). Data was collected correlating the activity of the new non-peptide src inhibitors in the Cellular Mimetic assay with that obtained in the LA25 src transformed cell line (see below).

When these two assay conditions were applied to some of the pentapeptide-based PKA inhibitors, which were designed as illustrated in Figure 3, the results shown in Table 1 were obtained. The same assay conditions were also applied to the analogously designed pentapeptide-based src inhibitors and obtained the results shown in Table 2.

The standard pentapeptide sequence chosen for the majority of PKA inhibitors in Table 1 was derived from the pseudosubstrate sequence of the peptide inhibitor which was bound to PKA, when the crystal structure illustrated in Figure 1 was

solved. The standard pentapeptide sequence used for src in Table 2, Ac-Ile-AA-Gly-Glu-Phe-NH₂, was described in Nair, Kim et al., 1995. Some of the chemistry used to prepare the PKA inhibitors is described in Nair, Lee & Hangauer 1995. The synthetic methodology used to develop a number of the src inhibitors is described in
5 Lai et al., 1998.

The collective results in Tables 1 and 2 show that both the serine kinase PKA and the PTK src can accommodate a variety of large polar M₁ functional groups at the P 0 phosphorylation position. Furthermore, using the STAIRe methodology (see Choi et al. 1996), the sulfamic acid inhibitor **8**, and related inhibitors, were shown to
10 actually bind best when MgATP (not MgADP or no nucleotide) is also bound. This was a somewhat surprising result since these inhibitors are analogs of the “end product inhibitors” **1** & **12** which must bind simultaneously with MgADP just following phosphate transfer in the generally accepted reaction mechanism for protein kinases.

These results also demonstrate that both PKA and src can show a large difference in binding affinity for structurally very similar inhibitors. For example, the sulfamic acid PKA inhibitor **8** (Table I) has a K_i of 0.16 μM under Literature Mimetic assay conditions (L) whereas the isosteric sulfonamide **7** is 1,875 X less potent (K_i = 300 μM). The sulfamic acid inhibitor **8** is also isosteric with the end product
15 phosphate inhibitor **1** yet it binds much more tightly under both Literature Mimetic assay conditions (31 X) and Cellular Mimetic (C) assay conditions (108 X). The beneficial effect of an oxygen atom positioned analogously to that in the substrate Ser is illustrated by comparison of phosphonate **2** to phosphate **1** and also ether **6** to phosphate **1**. This oxygen atom can also be positioned as a serine-like OH side chain
20 and enhance binding (compare **2** to **3A** and **4A**) wherein the closer serine mimic **4A** is the more active. The difference in activity of the diastereomeric inhibitors **3A** or **B** and **4A** or **B** suggests a specific interaction with the active site catalytic residue Asp-166 may in fact be occurring as intended in the M₁ design (Figure 3).

TABLE I
INITIAL M₁ SCREENING RESULTS WHILE APPENDED
TO THE PKA PENTAPEPTIDE SCAFFOLD

- - - - = Attachment Point









	K_i (μ M), (Conditions*)		K_i (μ M), (Conditions*)
	* L=Literature Mimetic C=Cellular Mimetic		* L=Literature Mimetic C=Cellular Mimetic
1 M ₁ = (End Product Inhibitor)	5 (L) 108 X 542 (C)	7 M ₁ =	300 (L) 8 X 2400 (C)
2 M ₁ =	76 (L) NT (C)	8 M ₁ =	0.16 (L) 31 X 5 (C)
3 M ₁ =	18 (L)-Diastereomer A 72 (L)-Diastereomer B NT (C)	9 M ₁ =	250 (L) 8 X 2100 (C)
4 M ₁ =	4 (L)-Diastereomer A 20 (L)-Diastereomer B 171 (C)-Diastereomer A 1510 (C)-Diastereomer B	10 M ₁ =	38 (L) 3 X 115 (C)
5 M ₁ =	5 X=H 28 (L) 29 X 780 (C)	11 M ₁ =	45 (L) NT (C)
6 X=CO ₂ H	6 (L) 75 X 450 (C)		

The src inhibition results (Table II) show that the end product inhibitor **12** drops in activity upon going from Literature Mimetic assay conditions to the higher ionic strength Cellular Mimetic assay conditions analogous to the PKA end product inhibitor **1**. However, whereas all of the PKA inhibitors with polar M₁ functional groups were less active under Cellular Mimetic assay conditions three of the src inhibitors **14**, **15**, & **17** held their activity under these higher ionic strength assay conditions. Also, the hydroxyphosphonate src inhibitor **13** (a mixture of the R and S diastereomers) is analogous to the PKA inhibitor **3A** and both are roughly in the same

activity range as their corresponding end product inhibitors, **12** & **1** respectively, under Literature Mimetic assay conditions. Shortening the side chain length in the phosphonate src inhibitor **13** by one carbon atom (and necessarily removing the attached OH at the same time) to give **14** improved the activity (analogous to the PKA inhibitor comparison **3** to **4**) and, more importantly, resulted in equivalent activity under Cellular Mimetic assay conditions. The src results with **16-19** (particularly **17**, see later for an analogous α -tricarboxyl acid M_1 analog appended to non-peptide src inhibitors) also suggests that similar amides may be useful M_1 functional groups to explore with non-peptide src inhibitors.

Non-peptide src inhibitors are preferred to peptide scaffold based compounds, partly because some of these inhibitors have a dual effect on src. For example, phosphonate inhibitor **14** not only inhibits src by competitively binding in the active site but it also activates src by binding to the SH2 site thereby releasing the intramolecular autoinhibition mechanism (Xu et al., 1997). This opposing effect gives an unusual IC_{50} curve for **14** wherein at low inhibitor concentrations src is stimulated (to a maximum of 70%) in a smooth dose-response fashion (due to initial tighter SH2 binding) followed by a typical IC_{50} inhibition curve at higher inhibitor concentrations (due to lower affinity blockade of the active site). This opposing activation effect of the pentapeptide inhibitors makes them appear to be less potent active site inhibitors than they in fact are, and makes it difficult to accurately rank M_1 groups while appended to this pentapeptide scaffold. However, the better M_1 groups identified with the src pentapeptide scaffold must still be accommodated in the catalytic region of the active site and hence are useful orienting groups for the ongoing non-peptide src inhibitor studies as intended. Since PKA does not have an SH2 domain this complication is not a factor in interpreting the PKA pentapeptide inhibitor M_1 testing data.

TABLE II
INITIAL M₁ SCREENING RESULTS WHILE
APPENDED TO THE SRC PENTAPEPTIDE SCAFFOLD

Inhibitor (1 mM)		% Inhibition of 2 mM RR-src phosphorylation by src Assay Conditions		Inhibitor (1 mM)		Literature Mimetic	Cellular Mimetic
		Literature Mimetic	Cellular Mimetic				
12 M ₁ = 		36	0	16 M ₁ = 		60	8
13 M ₁ = 		51	0	17 M ₁ = 		20	28
14 M ₁ = 		83	88	18 M ₁ = 		64	5
15 M ₁ = 		68	59	19 M ₁ = 		24	0

5 The results in Tables 1 and 2 also show how much effect the assay conditions can have on both inhibitor potencies and the rank order of activity. For example, as shown in Table 1, switching from the Literature Mimetic (L) assay conditions to the Cellular Mimetic (C) assay conditions can change the potency from as little as 3-fold (inhibitor **10**) to as much as 108-fold (inhibitor **1**). Also, whereas inhibitor **10** is less

10 potent than **1** under Literature Mimetic conditions it is more potent under Cellular Mimetic conditions. The src inhibitor data presented in Table 2 show that many of the inhibitors lose their potency upon going from Literature Mimetic assay conditions to Cellular Mimetic assay conditions. The rank order of potency against src is also sensitive to the assay conditions. Whereas inhibitor **18** is more potent than inhibitor

15 **17** under Literature Mimetic conditions, the opposite is true under Cellular Mimetic conditions. Since activity within cells is the goal, the Cellular Mimetic src assay was selected as the standard assay for testing potential non-peptide src inhibitors. Activity within the Cellular Mimetic assay is a necessary, but not sufficient, condition for activity within cells. As will be described later, the Cellular Mimetic src assay will be

20 followed up with cell culture assays wherein cell penetration, metabolism and binding to other cellular components are also factors in the measured potency.

The next class of M₁ functionality which was explored was the boronic acid group. This functional group is an intriguing candidate for M₁ for a number of reasons: 1) It can exist in a non-ionic state so that it should not prevent passive





25 absorption of non-peptide inhibitors across cell membranes. 2) The planar, trigonal,

boron acids might form reversible tetrahedral covalent borate complexes (a well known property of boronic acids, see Loomis & Durst., 1992) through their vacant 2p orbitals with anions present in the protein kinase active site such as the catalytic Asp carboxyl group or the ATP/ADP terminal phosphate oxygens. This ability to form borate complexes with active site nucleophiles has been extensively utilized to develop slow binding inhibitors of serine proteases (e.g. see Kettner & Shenvi, 1984), wherein the nucleophilic serine OH forms a covalent bond with the vacant 2p orbital in the boronic acid resulting in a tetrahedral borate complex (e.g. see Skordalakes et al., 1997). Also, an intramolecular complex of a boronic acid with a urea NH₂ was used to prepare transition state analogs inhibitors of dihydroorotase (Kinder et al., 1990). 3) Boronic acids act as Lewis acids and are converted to tetrahedral hydrates in water by forming borate complexes with water or hydroxide ions. Therefore, it is also possible that these boronic acid hydrates may function as phosphate mimics and M₁ modules as proposed in Figure 2. This hydration property was utilized by Baggio et al. (1997) wherein a hydrated boronic acid functioned as a transition state analog inhibitor functionality for arginase. These researchers evaluated the inhibited complex by x-ray and showed that the hydrated boronic acid functionality formed two hydrogen bonds with the active site catalytic Glu-277 carboxyl side chain and one of the other hydrated boronic acid OH's interacted with two catalytic Mn²⁺'s in the active site. These binding interactions are closely analogous to those proposed in protein kinase active sites, i.e. H-bonds to the catalytic Asp side chain carboxyl group and interactions with the active site Mg²⁺'s (see Figure 2), and 4) The use of boronic acids for protein kinase inhibitors has not been explored previously.

In the area of pentapeptide-based PKA inhibitors, the boronic acid functionality has been prepared and tested as a potential M₁ module utilizing the four inhibitors **21-24** shown in Table 3 (see Hsiao & Hangauer, 1998, for some of the chemistry used to prepare these compounds).

TABLE III

PKA INHIBITION RESULTS WITH BORONIC ACID-CONTAINING PEPTIDE INHIBITORS

Ac-RRGXl- NH ₂ , X =	IC ₅₀ μM (cond. L, 0 h preincubation)	IC ₅₀ μM (cond. L, 4 h preincubation)	IC ₅₀ μM (cond. C, 0 h preincubation)	IC ₅₀ μM (cond. C, 4 h preincubation)
20 Ala	278 (K _i = 9 μM)	417	41 (K _i = 25 μM)	50
21 	249	* 500 μM 34% inh	764	* 2000 μM 19% sti
22 	81	* 65	* 1753	* 2000 μM 71% sti
23 	398	133	2000 μM 16% inh	* 2000 μM 5% inh
24 	1000 μM 33% inh	1000 μM 44% inh	2000 μM 6% sti	1734 μM

* Very distorted IC₅₀ curve: Suggests Inhibitor is also a substrate.

L = Literature Mimetic Assay Conditions.

C = Cellular Mimetic Assay Conditions.


Inh = Inhibition.

Sti = Stimulation.

While testing these boronic acid-containing PKA inhibitors, the corresponding pentapeptide pseudosubstrate inhibitor **20** was included as an internal control while investigating time-dependent inhibition as shown in Table 3. Under Literature Mimetic assay conditions, and no preincubation, the initial results suggested that the shortest chain L-amino acid **21** was binding with the same affinity as the pseudosubstrate inhibitor **20** (i.e. K_i ca. 9 μ M). As this side chain was increased in length (to **23** and then **24**) binding affinity appeared to decrease. When the stereochemistry of the unnatural amino acid was inverted from L in **21** to D in **22**, binding affinity appeared to increase 3-fold. This improvement in binding may occur as a result that the boronic acid OH in **21** is positioned at the same chain length as L-homoserine whereas the natural substrate, L-serine, has a one carbon shorter side chain. Modeling results with the PKA ternary structure indicated that the boronic acid OH can be retracted back somewhat by inverting the α -carbon stereochemistry from L in **21** to D in **22** and then repositioning the side chain to more closely mimic the

positioning of the natural substrate L-serine OH adjacent to the catalytic residues (Asp-166 and Arg-168). The modeling results were subsequently supported by the finding that, upon incubation of PKA with these inhibitors for up to 4 hours without adding the competing peptide substrate (Kemtamide: LRRASLG-NH₂), both 21 and 22 function as substrates with the D-diastereomer 22 being phosphorylated faster.

The fact that these boronic acid inhibitors are also substrates, became much more obvious by the greatly distorted IC₅₀ curves obtained under the Cellular Mimetic conditions, both with and without preincubation (both PKA and src are more active enzymes under the Cellular Mimetic conditions than under Literature Mimetic conditions). In the assay used to obtain these results, the P³² phosphorylated Kemtamide product (25 generated from γ -P³² ATP) was isolated at the end of the substrate incubation period by binding to phosphocellulose filter paper via the three cationic groups (two Arg's and the N-terminus) and the level of phosphorylated product isolated on the paper is then measured by liquid scintillation counting (cpm's). The boronic acid inhibitors 21-24 have two Arg's in their sequence also and therefore will bind to the phosphocellulose paper in addition to Kemtamide (although not as consistently or completely due to one less positive charge). Consequently, when analyzed as inhibitors, the amount of phosphorylated Kemtamide produced was not only counted, but also the amount of phosphorylated inhibitor simultaneously produced (e.g. see 26 below). The net result is that distorted IC₅₀ curves are obtained which show net "stimulation" at higher inhibitor concentrations in some cases. The D diastereomer 22 gives the greatest apparent "stimulation" (71%) when preincubated with PKA for 4 hours under Cellular Mimetic conditions followed by the L diastereomer 21 (19%) and then the one carbon homolog 23 (5%) indicating all three are substrates for PKA (Table III). The underlying substrate behavior of these "inhibitors" makes an accurate measurement of their inhibition potency impossible with the current assay. However, it does appear from the data that homologating the boronic acid functionality out with only CH₂ groups (homologations with boronic acid non-peptide src inhibitors may also be carried out) decreases the binding affinity and ability to function as a substrate.



The boronic acid “inhibitors” 21 and 22 were shown to be substrates for PKA by running the same assay, but without adding Kemptamide, and stopping the reaction at various time points as shown in Figure 4. The graphs show their respective rates and levels of phosphorylation with the typical loss of initial velocity kinetics with time (due to substrate depletion and end product inhibition), analogous to a standard L-Ser substrate such as Kemptamide. The comparison of 21 to 22 shown was done in the same assay run, at identical boronic acid substrate concentrations, and with identical Cellular Mimetic assay solutions so that the cpm’s could be directly compared. The graphs show that initial velocity conditions were lost within one hour for D isomer 22 whereas the linearity appears to have been lost somewhat slower with the L isomer 21 suggesting a slower consumption of starting material. That the boronic acid moiety would be phosphorylated by PKA was surprising, but it is even more surprising that the phosphonic-boronic acid mixed anhydride produced (e.g. 26) was stable enough to survive the pH 7.2/37°C assay incubation and then be isolated by binding to phosphocellulose paper after acid quenching of the reaction with 10% TCA and washing the phosphocellulose paper with 25 mM phosphoric acid (3X). An STN substructure search was run on mixed anhydrides of phosphoric and boronic acids and found only three references to experiments and theoretical calculations for the analogous putative (but not proven) anhydride formed from boric acid and phosphoric acid as a solid surface impregnated catalyst for the partial oxidation of ethane to acetaldehyde at 823 °K (Zhanpeisov & Otsuka, 1992, Otsuka et al., 1992, Murakami et al., 1990). However, this highly unusual anhydride has never before been synthesized free of a solid surface, isolated or characterized. Thus, this is a novel enzymatic reaction and chemical entity with interesting possibilities for protein kinase inhibitor designs.

The src and PKA pentapeptide scaffold tethered M₁ evaluations described above have resulted in identifying a variety of orienting M₁ groups which could be used for screening potential non-peptide scaffolds as indicated in Step 1 (Figure 1). The boronic acid (from **22**), the phosphonate (from **14**), and the sulfamic acid (from **8**) were initially chosen from the menu of potential M₁'s for the src non-peptide scaffold screening. Among these choices, the boronic acid M₁ group has proven effective for Step 1 screening of non-peptide scaffolds.

The most useful crystal structures available for the design of non-peptide src inhibitors, which do not compete with ATP, are the native src structure and the IRTK:peptide:AMP-PNP ternary structure. For all of the modeling studies discussed below, the SYBYL molecular modeling software package is used on a Silicone Graphics Workstation.

Since the src and IRTK structures are only used as qualitative guides in designing the non-peptide scaffolds and combinatorial libraries, the active sites along with two layers of surrounding residues were carved out from the native src and IRTK ternary structures, analogous to the previous PKA modeling studies. The IRTK:peptide:AMP-PNP ternary structure active site region was used as the template structure to guide the building of the src residue sequence 424-418 back onto the src structure using the comparative homology modeling technique (see Hutchins & Greer, 1991). These residues were disordered in the native src crystal structure and therefore not visible by x-ray. They were reintroduced because they help form the P+1 to P+3 binding sites for peptide substrates which are important for some of the modeling studies. The analogous residues in the IRTK ternary structure are seen by x-ray and directly interact with the bound peptide substrate. In fact, it is probably the presence of the bound peptide substrate which induces order in the positioning of this sequence so that it is visible by x-ray. The src pentapeptide substrate Ac-Ile-Tyr-Gly-Glu-Phe-NH₂ (Nair et al., 1995) was then docked into the src active site again using the IRTK ternary structure as a template. Small adjustments were then manually made to partially clean up this complex, all of the hydrogen atoms were added, appropriate formal and partial charges (calculated via the Gasteiger Marsili method) were added, and then the entire complex was subjected to 300 iterations of molecular mechanics minimization using the Tripos force field, analogous to the previous PKA modeling procedure. A schematic representation of this modeled complex is given in Figure 5.

Any inaccuracies in this src:peptide and the src:inhibitor models are accommodated by experimentally evaluating a range of side chains, the number and diversity of which is scaled roughly to the level of uncertainty for the structure of their particular binding region in the src model active site (see later), in a combinatorial fashion.

5 As shown in Figure 5 the residues 424-418 built back into the src interact with the P+1 to P+3 substrate residues, Gly-Glu-Phe-NH₂ respectively, through beta sheet type hydrogen bonding interactions with the substrate main chain (analogous to the IRTK peptide substrate). Lys 423 engages in two important interactions: 1) the β and γ CH₂'s fold over the top of the P 0 Tyr phenyl ring engaging in a hydrophobic
10 binding interaction and then 2) the remaining CH₂-CH₂-NH₃⁺ of this side chain extends away to form a salt bridge with the P+2 Glu side chain as indicated. The rest of the P 0 Tyr hydrophobic binding pocket is formed by Pro 425 under the phenyl ring and part of the Cys 277 side chain above the phenyl ring. Using a large combinatorial peptide src substrate library, Songyang et al. (1995) found that the most commonly
15 chosen side chain for the P+1 position was Gly followed by Glu. The present model indicates that a P+1 Glu side chain may form a salt bridge with nearby Arg 469 as indicated in Figure 5. Previously, researchers found that only Glu was chosen for the P+2 position and the present model indicates that this side chain forms a salt bridge with the Lys 423 side chain. At the P+3 position Phe was very strongly preferred and
20 the model indicates that this side chain forms a stacking interaction with the Phe 424 side chain. At the P-1 position Songyang et al. found that Ile was the most preferred residue followed by Val and then Leu. The model shows a hydrophobic pocket for binding the P-1 side chain formed mainly by Trp 428, Ala 390 and Leu 347. One might expect that the P 0 Tyr side main chain will strongly interact (though hydrogen
25 bonding) with the active site in a catalytically competent complex because enzymes often form more critical interactions in this region close to where the reaction will be occurring. The IRTK ternary complex does not show a good hydrogen bond to either the P 0 Tyr NH or carbonyl. The nearest candidate residue for this interaction in the IRTK structure is Asn 1215 wherein the side chain NH₂ is 3.71 Å from the Tyr
30 carbonyl oxygen. When the IRTK ternary structure is overlayed onto the src native structure, using the four residues mentioned in the Background and Significance section, Asn 468 from the src structure was found to be positioned very close to the analogous IRTK Asn 1215. This suggests that this conserved residue is performing

an important role and might move a little closer (i.e. about 1 Å) to the substrate P 0 NH and carbonyl in a catalytically active complex and form the hydrogen bonding interactions indicated in Figure 5. Finally, the catalytic Arg 388 and Asp 386 are correctly positioned in the src model to catalyze the transfer of the γ -phosphate from ATP to the Tyr OH.

The src:peptide substrate complex can now be used to model potential non-peptide scaffolds and determine preferred substitution positions for the specificity elements, all with an appropriately attached M₁ functionality, before choosing new scaffolds to experimentally evaluate. The IRTK:peptide:AMP-PNP ternary structure can also be used to model these potential scaffolds and preferred substitution positions. These scaffolds have broad utility for the development of selective PTK inhibitors by further developing them with appropriate specificity elements following the strategy outlined in Figure 1.

The first non-peptide scaffold evaluated with this src:peptide substrate model was the naphthalene scaffold. This is the first use of bicyclic aromatic scaffolds for non-peptide PTK inhibitors, which do not compete with ATP. The naphthalene scaffold's utility for this purpose was demonstrated by developing a non-peptide inhibitor of the IRTK and EGF receptor PTK (Saperstein et al., 1989). The IRTK ternary complexes were subsequently used to adapt this scaffold for src inhibition (see Marsilje et al., 2000). The naphthalene scaffold was docked into the src active site by first carrying out a least squares fitting of atoms *a-d* onto the peptide substrate as indicated in Figure 6. In this way the naphthalene scaffold is related to the peptide substrate by the cyclization shown by the arrow in Figure 6 and an appended OH as a substitute for the substrate Tyr NH. This is essentially the same process used to dock this scaffold into the IRTK structure as described in Marsilje 2000. The peptide substrate was then deleted from the active site, various M₁ functional groups and specificity elements S₂ & S₃ were then added to the scaffold as indicated and the complexes were then individually minimized for 300 iterations. This same process was also used to design the isoquinoline and indole scaffolds whose binding modes are indicated in Figure 7.

In all of these modeled complexes selectivity element S₂ consists of various hydrophobic side chains which can bind in the same pocket as the substrate P-1 Ile side chain and selectivity element S₃ consists of various molecular fragments which

can bind in the P+1 to P+3 region of the peptide substrate binding sites (Figure 5). Since the active site region where M₁ binds is highly conserved among all of the protein kinases, the small menu of M₁ functional groups previously identified using peptide scaffolds served as the initial M₁ groups for attachment to the scaffolds at the indicated positions. Of the two selectivity elements binding sites, the structure of the hydrophobic binding cavity for S₂ is known with greater confidence in the src model than is the P+1 to P+3 binding region for S₃. This is because the S₃ binding site was constructed partially by comparative homology modeling whereas the S₂ site is largely unchanged from the structure determined by x-ray for native src. In view of these varied levels of confidence in the modeled binding sites for M₁, S₂ and S₃, the combinatorial library diversity is scaled such that the greatest variety and number of side chains in the combinatorial libraries are at the S₃ site followed by the S₂ site and then M₁.

The src results using M₁ functional groups to experimentally identify promising non-peptide scaffolds are listed in Table 4. The data in Table 4 allows a number of conclusions to be drawn: 1) Low, but measurable, inhibition potency can be obtained with an appropriate M₁ group attached to a scaffold (e.g. 27 & 38). 2) 1 mM inhibitor concentrations for this type of screening is higher than desirable but 100 μM is too low. Screening of scaffolds bearing an M₁ group would optimally be conducted at 500 μM. 3) The boronic acid, sulfamic acid and phosphonic acid M₁ functional groups, which had been identified using the PKA pentapeptide scaffold (22, Table 3 & 8 Table 1) or the src pentapeptide scaffold (14, Table 2), respectively, give measurable activity when placed at the 2 position of the naphthalene ring (27, 28 & 30, respectively), the preferred position for M₁ identified in the model naphthalene inhibitor:src complex (Figure 6). Moving the boronic acid or phosphonic acid M₁ groups to the 1 position (32 or 33) reduced activity. 4) The related M₁ sulfonamide functionality, which was poor on the PKA pentapeptide scaffold (7 & 9, Table 1) is also poor when appended to the 2 (31) or 1 (34) position of the naphthalene scaffold. The sulfonic acid analog at the naphthalene 2 position (29) is completely inactive, even at 1mM. 5) The naphthalene scaffold can be replaced with a benzofuran (35) or a benzothiophene (36) scaffold without a noticeable reduction in activity when the boronic acid M₁ group is positioned analogous to the 2 position on a naphthalene. 6) The boronic acid M₁ group also provides active compounds when appended to the

isoquinoline (37) or indole (38) scaffolds at the positions indicated by modeling results (Figure 7). However, the indole scaffold is clearly favored over the isoquinoline scaffold suggesting that a hydrogen bond donating ability to Asn 468 (see Figure 7) is important for higher activity (this would require the protonated isoquinoline which is disfavored by the adjacent electron withdrawing ester group). This conclusion is also supported by considering that a peptide substrate may position a hydrogen bond donating peptide bond NH at a similar position (Figure 6) and by finding that an equivalently positioned phenolic OH (Figure 6) improves potency (phenolic OH's are much better H-bond donors than acceptors) 8) When directly compared to other M₁ groups the boronic acid group is superior (e.g. 27 vs. 28-31, 38 vs. 39). 9) A biphenyl scaffold modeled into the src and IRTK active sites and found promising binding modes for this scaffold. Combinatorial libraries were developed with the biphenyl scaffold (see Pavia et al., 1996), and the modeling results were encouraging. Therefore, the para (40) and meta (41) isomers were evaluated with the boronic acid M₁ group. Both biphenyl compounds showed potency equivalent to the best naphthalene boronic acid (27) and therefore provide another scaffold geometry (the two phenyl rings are not planar) for further evaluation and development.

Since the bare scaffolds, with only an M₁ group appended, often have low binding affinity, the IC₅₀'s and K_i's for the 2-naphthalene boronic acid and sulfamic acid inhibitors were determined to ensure that a typical dose/response IC₅₀ curve is obtained. This analysis provided the typical shape dose/response curves seen with more potent inhibitors. The IC₅₀'s and K_i's of these simple inhibitors also confirmed that the boronic acid inhibitor 27 is the more potent than the sulfamic acid analog 28 and has a K_i of about 554 μ M.


















The next issue addressed with these simple inhibitors before proceeding to elaborate them further was their mode of inhibition, specifically whether they are ATP-competitive inhibitors. In the case of the naphthalene inhibitors 27 & 28, their IC₅₀'s were monitored as the ATP concentration was increased in three steps up to 1 mM. As a comparison, the IC₅₀ of the pentapeptide phosphonic acid src inhibitor 14 (Table II) was also monitored. If any of these inhibitors were competing with ATP, then their IC₅₀'s should have increased proportionally with the ATP concentration (i.e. the dashed line). As shown, the IC₅₀'s for all three inhibitors remained essentially constant as the ATP concentration was increased demonstrating that they

are not ATP-competitive inhibitors. A very similar, but much less costly (commercial src is expensive), analysis was conducted with the indole boronic acid inhibitor 38. In this case, the % inhibition was monitored with 38 at a constant 500 μ M inhibitor concentration but with increasing ATP concentrations of 200, 500 and 1,000 μ M.

- 5 Once again the inhibitor potency was not reduced by the increasing ATP concentration demonstrating that 38 is also non-ATP competitive.

The initial results obtained in Step 1 suggests that it is possible to identify promising scaffolds for further elaboration with this procedure. The biggest uncertainty with Step 1 is that some of the scaffolds identified in this way might not
10 be binding in the fashion suggested by the prior modeling evaluations. This is essentially a “false positive” problem. These “false positives” will likely fail in Step 2 , when they are evaluated for improved binding using the modeled complexes as a guide. Some false positive results can be accepted in Step 1 because the bare scaffolds with only the M_1 group attached are easily obtained. For further inhibitor
15 development, one may return to Step 1 each time new scaffolds are needed to carry through Steps 2 & 3. The best M_1 generated can be used each time Step 1 is repeated. Currently, the boronic acid M_1 group is preferred since it has a proven ability to give measurable activity with bare scaffolds. Also the boronic acid M_1 group offers multiple interesting possibilities for covalent and non-covalent interactions with the
20 conserved catalytic residues since it can: 1) hydrate, 2) form borate complexes with electron rich active site atoms, and/or 3) be phosphorylated and then react with active site nucleophiles or engage in additional non-covalent interactions. From the data in Table 4, the naphthalene and indole scaffolds were chosen as M_2 for the first efforts in Step 2 (the biphenyl scaffold is also a preferred scaffold). It is also worth mentioning
25 that naphthylalanine and analogs can be successfully substituted for the P 0 tyrosine in src peptide substrates (e.g. see Alfaro-Lopez et al., 1998) further supporting the notion that naphthalene and related scaffolds can bind at the P 0 site.

TABLE IV
INITIAL STEP 1 RESULTS
% SRC INHIBITION IN CELLULAR MIMETIC ASSAY

Inhibitor	% Inhibition of 2 mM RR-src at Inhibitor Concentration ()		Inhibitor	% Inhibition of 2 mM RR-src at Inhibitor Concentration ()
 	--- = Attaching bond 59 (1 mM) 13 (100 μM) IC ₅₀ =950 μM K _i =554 μM	NON-ATP COMPETITIVE	 X=O	10 (100 μM)
	31 (1 mM) IC ₅₀ =1.6 mM K _i =963 μM	NON-ATP COMPETITIVE		13 (500 μM)
	0 (1 mM)			
	14 (1 mM)			62 (500 μM)
	0 (100 μM)			11 (500 μM)
 	0 (100 μM)			13 (100 μM)
	1 (1 mM)			14 (100 μM)
	0 (100 μM)			

5 In comparing the naphthalene vs. indole scaffold results with a boronic acid M₁ group (i.e. **27** vs. **38**, Table 4) the indole hydrogen bond donating NH and/or the adjacent ester group appeared to be the reason for the enhanced potency. Consequently, for Step 2 one of the first attempts was to add a hydroxyl group and an amide (with S₂) to the naphthalene scaffold at the adjacent positions suggested by the modeling results (Figure 6). For the indole scaffold one priority was to prepare some amide analogs to see if potency can be increased with the S₂ specificity element

10












(Figure 7). In order to facilitate the synthesis of these initial analogs, an OH was temporarily substituted for the boronic acid M₁ group. The OH group is also known to interact with the catalytic residues, as required for an M₁ group, because it is the natural substrate M₁ whose phosphorylation rate is accelerated by interactions with the catalytic residues. The results obtained for some of the initial analogs are given in Table 5 along with a side by side comparison, in the Cellular Mimetic src assay, to two literature src inhibitors **50** & **51** which are reported be non-ATP competitive. Some of these results and additional analogs are described in Marsilje 2000.

Inhibitor **50**, and analogs (Huang et al., 1995), were of particular interest because the iminochromene scaffold is closely related to the naphthalene scaffold and it's binding mode would be expected to be very similar based upon the model (Figure 6). Partly because of this close analogy, the amides of hydroxyanilines with the naphthalene and indole scaffolds were examined as shown in Table 5. Also, the modeling studies with these hydroxyaniline amides derivatives in the src active site indicated that the hydroxyl group may be able to engage in a hydrogen bonding interactions with the src Phe 424-Ala 422 backbone peptide bonds analogous to peptide substrates (see Figure 5). These modeling studies also indicated that the homologous hydroxybenzylamides should be active and, more importantly, provide a substitution position (i.e. the benzylic carbon) for appending side chains to bind in the P-1 side chain pocket (e.g. to Arg 469, Figure 5).

The data in Table 5 allow the following conclusions to be drawn: 1) Adding an amide extension onto both the naphthalene and indole scaffolds can increase potency as predicted by the models for these scaffolds bound in the src active site (ca. 5-fold in the cases of **42** vs. **43**-meta & **47** vs **48**). 2) Adding a hydroxyl group to the naphthalene scaffold adjacent to the amide increases potency (about 5-fold, **43**-meta vs. **44**) as predicted by the src model, and also suggests Asn 468 does hydrogen bond with this OH. 3) Moving the M₁ OH group from the position predicted to be best in the src model to the adjacent position reduces potency by one order of magnitude (**43**-meta to **45**). 4) The indole scaffold is less responsive than the naphthalene scaffold to regiochemistry of the hydroxyaniline extension (**48** vs. **43**). 5) The naphthalene and the indole scaffolds accept the one carbon homologation provide by using hydroxybenzylamides (**46** vs. **43** & **49** vs. **48**). 6) The two M₁ hydroxy regioisomers of the naphthalene scaffold are both non-ATP competitive (see Marsilje 2000). 7) All

of the methyl hydroxyaniline and hydroxybenzylamide inhibitors were found to be less active suggesting that the hydroxyl group in the amide extension is functioning as a hydrogen bond donor. In this regard it is worth mentioning that in another src peptide substrate combinatorial library study Ser and Thr were identified as two of the most preferred residues at the P+2 position (Alfaro-Lopez et al., 1998) suggesting that there are other binding opportunities for an amide extension OH other than to the Phe424-Ala 422 peptide bonds suggested by the modeling studies. 8) The most potent non-ATP competitive, non-peptide, src inhibitor previously disclosed in the literature (50) is not nearly as potent as reported when tested under the Cellular Mimetic assay conditions ($IC_{50}=118$ nM reported by Huang et al., 1995 vs only 30% inhibition at 100 μ M) and is less potent than a number of the current inhibitors (especially 43-meta) including the most analogous inhibitor (50 vs. 45). The structure-activity-relationship (SAR) reported for hydroxy regioisomers of 50 in their assay (Huang et al., 1995) also does not correspond with the SAR which was obtained for the related naphthalene inhibitors. For example, their iminochromene analog of the most potent naphthalene inhibitor 43-meta is 230-fold less potent than 50 in their src assay. An important advantage of the naphthalene scaffold over the iminochromene scaffold is that it allows a highly desirable S_2 specificity element to be added for accessing the P-1 hydrophobic site (see Figure 6) whereas the analogous position can not be substituted on the iminochromene scaffold because it is occupied by the ring oxygen atom.

TABLE V
INITIAL STEP 2 RESULTS
% SRC INHIBITION IN CELLULAR MIMETIC ASSAY

Inhibitor	% Inhibition of 2 mM RR-src at Inhibitor Concentration ()	Inhibitor	% Inhibition of 2 mM RR-src at Inhibitor Concentration ()
<u>42</u>	 47 (100 μ M)	<u>47</u>	 40 (500 μ M)
<u>43</u>	 Ortho 39 (100 μ M) Meta: 89 (100 μ M) IC ₅₀ =18 μ M, K _i =10 μ M Para 23 (100 μ M) <i>NON-ATP COMPETITIVE</i>	<u>48</u>	 Ortho. 43 (100 μ M) Meta 30 (100 μ M) Para 45 (100 μ M)
<u>44</u>	 45 (100 μ M)	<u>49</u>	 Ortho 24 (100 μ M) Meta In progress Para 54 (100 μ M)
<u>45</u>	 51 (100 μ M) IC ₅₀ =170 μ M <i>NON-ATP COMPETITIVE</i>	<u>50</u>	 Huang et al 30 (100 μ M) Lit IC ₅₀ = 118 nM
<u>46</u>	 Ortho 42 (100 μ M) Meta In progress Para 42 (100 μ M)	<u>51</u>	 ST 638 37 (100 μ M) Lit IC ₅₀ =18 μ M
		<u>52</u>	 Piceatannol 41 (100 μ M) Lit IC ₅₀ = 66 μ M for p56 ^{lck}

5 The inhibitor potencies in the src Cellular Mimetic assay can be further calibrated against other literature non-ATP, non-peptide src inhibitors. Two additional examples are 51 (ST 638, Shiraishi et al., 1989) which is a member of the “tyrphostin” family of erbstatin analogs (see Lawrence & Niu, 1998) and the natural product PTK inhibitor piceatannol 52 (Thakkar et al., 1993). In the Cellular Mimetic

assay all of these known inhibitors are less potent than had been reported suggesting that the assay is particularly demanding in terms of achieving high potency. The initial testing of src inhibitors is carried out using a single concentration (in triplicate) because commercial src is too expensive to do full IC₅₀ curves on every inhibitor. It should be mentioned, however, that an IC₅₀ dose response curve is not linear and the difference between ca. 50% inhibition at 100 μM and a ca. 90% inhibition at 100 μM is actually a factor of 10 and not a factor of 2 (e.g. **45** vs. **43**-meta). Consequently, the literature src inhibitors 50-52 are greater than an order-of-magnitude less active than the currently most potent inhibitor 43-meta.

The discrepancies found within the literature reporting the potency of these inhibitors, the sensitivity to assay conditions described earlier with the PKA inhibitors, and the lack of consistency among numerous labs and commercial protein kinase assay kits highlights this overlooked, but crucial, problem in the field. Although the inhibitors produced by the present invention may be more potent under other assay conditions, the Cellular Mimetic assay should be used, which mimics the intracellular physical chemical conditions as closely as possible, as the primary potency and rank order guide for evaluating the inhibitors before choosing compounds to proceed to whole cell or tissue assays. As will be discussed in more detail later, the most potent naphthalene-based inhibitor thus far from the Cellular Mimetic assay (i.e. **43**-meta, IC₅₀=18 μM & K_i = 10 μM) is also effective in specifically blocking pp60^{v-src} stimulated cell proliferation with a similar IC₅₀ of ca. 25 μM. This suggests that not only is the Cellular Mimetic src assay predictive, but also that this class of naphthalene-based inhibitors can readily pass through cell membranes and inhibit intracellular src.

Analogs of a number of the naphthalene and indole inhibitors above can be prepared with the boronic acid M₁ group in place of the M₁ OH and/or with a S₂ hydrophobic specificity element attached for binding in the src P-1 site as illustrated in Figures 6 & 7. The naphthalene and indole scaffolds can then be taken through to Step 3 as described below. Each time Step 2 is repeated with new scaffolds from Step 1, the best selectivity elements S₂ and/or S₃ which have discovered with previous scaffolds will be used in the combinatorial libraries of Step 3. Even though the optimal combination of M₁, S₂ and S₃ is likely to be different for each scaffold, those

found optimal with the previous related scaffold (e.g. going from the naphthalene to the indole scaffold) should be suitable for utilization as better initial specificity elements in Step 2 with the new scaffold. The same process will be repeated each time there is a need to try another scaffold until sufficient potency, selectivity and suitable pharmaceutical properties are achieved for the src inhibitors or, subsequently, for inhibitors of additional therapeutically important PTK's.

Some of the chemistry used to prepare the naphthalene inhibitors is described in Marsilje 2000. For attaching a boronic acid functionality in place of a M₁ hydroxyl groups in the src inhibitors from Table 5, the Pd (0)-catalyzed cross-coupling methodology was used wherein either an aryl triflate (Ishiyama et al., 1997) or an aryl halide (Ishiyama, 1995) can be coupled with the commercially available pinacol ester of diboron. An illustrative example was have recently completed is given in Figure 8.

The example shown in Figure 8 demonstrates that it is possible to selectively triflate the less hindered OH at the M₁ position and have proven this by its removal to **56** with subsequent ¹H NMR verification of the substitution pattern. The monotriflate **53** was then taken on to the desired boronic acid **55** as indicated. The same reaction sequence also works well for the regioisomer of **42** which corresponds to inhibitor **45** from Table 5. The synthetic scheme shown in Figure 9 can be followed, in order to attach hydrophobic S₂ selectivity elements to the naphthalene scaffold.

The naphthalene chemistry can be converted to the solid phase in preparation for synthesizing combinatorial libraries of this scaffold in a 96-well plate format. Thus far model chemistry has been carried out on the less active naphthalene regioisomer represented by **44** because this compound is readily obtained from commercially available 3,5-dihydroxy-2-naphthoic acid as describe in Marsilje 2000. The successful model reactions to date are shown in Figure 10.

These model reactions demonstrate that it is possible couple the naphthalene scaffold to the Wang resin (**63**) and then carry out chemistry on the triflate [in this case the Pd (0)-catalyzed cross-coupling to the boronic ester **64**] followed by cleavage under mild conditions (**65**). The ester in **63** can also be saponified for subsequent coupling reactions to form amides containing the S₃ selectivity elements.

The naphthalene scaffold currently provides three diversity sites to be explored in the combinatorial libraries, M₁, S₂ & S₃. Solid phase combinatorial chemistry with 96-well plate reactors similar to that used in previous studies (Pavia et

al., 1996). The greatest number and diversity of side chains will be used for S₃ followed by S₂ and then M₁ for the reasons discussed earlier. One possible overall synthetic strategy, based upon the synthetic model studies above, for preparing these libraries is shown in Figure 11.

5 Of course if problems arise with this route there are many other possibilities. For example, if the Mitsunobu coupling to give **67** proceeds in too low a yield (due to the increased steric congestion of the added adjacent allyl group-but perhaps not a problem given the 92% loading obtained in Figure 10) then the scaffold could be
10 tethered to a resin through the carboxyl group, rather than the OH, using the acylsulfonamide "safety catch" linker (Backes et al., 1996) and form the amides last (the excess amines can be removed after cleavage by filtering through an acidic resin). Likewise, other linkers and/or resins can be used if the reduction of the alkene in the presence of benzylic ethers (**67** to **68**) is desired but problematic. The first use of the chemistry proposed in Figure 11 will be to simply prepare a library of 96 amides,
15 containing the boronic acid M₁ group, without having the allyl side chain in place so that these two potential complications will not be a problem initially and the most promising S₃ elements can be quickly identified..

 At least 14 S₂ hydrophobic side chains (includes linear, branched and cyclic) are identified for further study (28 if the corresponding alkenes are also explored)
20 based upon the modeling of candidate side chains into the P-1 site of the src model (Figure 6) and on the commercial availability of the needed halides to prepare the corresponding Wittig reagents. At least 96 commercially available amines are available which will provide potential S₃ specificity elements including: 1) hydrocarbons (4), 2) alkyl groups containing hydrogen bond acceptors (4), 3) alkyl
25 groups containing both hydrogen bond acceptors and donors (19), 4) alkyl/aryl groups containing hydrogen bond acceptors and donors (25), 5) aryl hydrogen bond acceptors and donors (10), 6) heterocyclic hydrogen bond acceptors and donors (20), 7) side chains containing cationic groups (4), 8) side chains containing anionic groups (9), and the 3-amino phenol side chain from inhibitor **43**-meta as an internal control for
30 src activity. A broad range of amines were included for S₃, in order not to overly bias the library here due to the higher level of uncertainty for this binding site in the src model.

The indole scaffold can be developed into a combinatorial library in much the same fashion. In this case, the indole NH would be used as the tether point for attachment to the Wang (or other) resin since the analogous Mitsunobu reaction is known (Bhagwat & Gude, 1994). A large amount of synthetic methodology has been developed for the synthesis of substituted indoles and have designed a route to include the S₂ hydrophobic side chain (see Figure 7) (Ezquerro et al., 1996).

The triflate functionality formed in reaction 2 from intermediate **69** (Figure 11) can be converted to an amine (Wolfe et al., 1997) and then a series of amides or other amine derivatives following the reaction sequence shown in Figure 12. In fact, the triflate is a versatile synthetic handle and could be converted into other functional groups as well.

When the amine **72** is available, the known M₁'s (e.g. the sulfamic acid from src inhibitor **28** Table 5 and amide-acid **17** Table 3) can be evaluated with this more developed scaffold and evaluate some new amine derivatives as potential M₁'s. For example the hydrated tricarbonyl amide M₁ group shown in structure **73** (and its non-hydrated precursor) is accessible via the synthetic methodology (see Lai et al., 1996) and could form a variety of interesting interactions with the conserved catalytic residues.

Following the modeling procedure described above, a series of hydroxy-containing analogs of the boronic acid M₁ group shown in Figure 13 were modeled in the src and IRTK active sites and found the illustrated interactions/binding modes as some of the interesting possibilities. By phosphorylating the boronic acid additional interesting possibilities are available (e.g. suicide type inhibition via reaction of the resulting mixed anhydride with an active site nucleophile). The presence of additional hydroxyl groups on the Tyr-mimetic phenyl ring is necessary and common among many PTK inhibitors (e.g. Piceatannol **52**, Table 5) and was shown to be beneficial on the side chain with the PKA phosphonate inhibitors (e.g. **2** vs. **3** and **4**, Table I). Consequently, adding one or more OH's to the boronic acid inhibitor M₁ design as illustrated in Figure 13 may considerably enhance potency. These OH groups would also extend the boronic acid side chain past the catalytic Asp and Arg residues without suffering a penalty for covering them with hydrocarbon as was probably the case with the PKA boronic acid homologs (**23** & **24**, Table 3). One possible route to the hydroxyboronic acids **76** & **77** utilizes the chiral boronic ester

homologation methodology of Matteson (e.g. see Matteson et al., 1987, 1988 & 1990).

In a preferred embodiment of the invention, the first module is produced by attaching the first module to a peptide scaffold. One or more functional groups are identified which preferentially bind to catalytic residues of the protein kinase. Further, the first module is combined with the second module so that the second module substitutes for the peptide scaffold.

Preferred first modules have a functional group such as boronic acid, a hydroxyl group, phosphonic acid, sulfamic acid, a guanidino group, carboxylic acid, an aldehyde, an amide, and hydroxymethylphosphonic acid. The compounds of the present invention may have two or more functional groups within the first module. More preferred modules are boronic acid groups, a hydroxyl group, or an amide group. An even more preferred amide group is a vicinal tricarbonyl amide.

Preferred second modules include indole, naphthalene, biphenyl, isoquinoline, benzofuran, and benzothiophene. More preferred second modules are an indole or naphthalene. In some embodiments of the invention more than one first module may be bound to the second module. In addition, the first module may have a linear chain comprising between one and three carbon atoms which links the first module to the second module. In alternative embodiments, one of the carbon atoms in the linear chain is substituted with a nitrogen, oxygen or sulfur atom.

The methods and compounds of the invention are broadly applicable to any protein kinase. Preferred protein kinases are protein tyrosine kinases and protein serine kinases. Preferred protein tyrosine kinases are pp60^{c-src}, p56^{lck}, ZAP kinase, platelet derived growth factor receptor tyrosine kinase, Bcr-Abl, VEGF (vascular endothelial growth factor) receptor tyrosine kinase, and epidermal growth factor receptor tyrosine kinase, and epidermal growth factor receptor-like tyrosine kinases. A more preferred protein tyrosine kinase is pp60^{c-src}. Preferred serine protein kinases include MAP (mitogen activated protein) kinase, protein kinase C, and CDK (cyclin dependent protein kinase).

The method of the present invention may further consist of adding one or more specificity side chain elements to the combination of the first and second modules. Specificity side chains can increase potency and specificity of the inhibitor.

Once a promising second module is identified it is not necessary to repeat all the steps of the method. Rather, the first module, specificity side chains, or a combination the two may be modified to improve the original inhibitor, i.e an inhibitor which has an increased ability to inhibit protein kinase activity when
5 compared to the unmodified first inhibitor.

The present method is designed to preferentially provide protein kinase inhibitors which do not act by inhibiting ATP binding t the protein kinase. Inhibitors of protein kinases may be potent but often lack specificity and are therefore often not good drug candidates. Therefore, protein kinase inhibitors which inhibit protein
10 kinase activity but does not inhibit or only weakly inhibit ATP binding to the protein kinase are preferred.

The present invention also provides a method for testing compounds for an ability to inhibit protein kinase activity. Compounds are produced according to claim 1. The activity of the protein kinase is measured in the presence of the inhibitor at the
15 same temperature, pH, ionic strength, osmolarity, and free magnesium concentration as found in a cell which expresses the protein kinase. The level of protein kinase activity is compared to the level of activity from the protein kinase without the presence of the inhibitor. Such an assay system which mimics physiological conditions provides the most relevant inhibition data. The assay may be conducted in
20 an automated assay system. Furthermore, the assay may be combined with a combinatorial chemistry method to rapidly screen numerous candidates.

The Pierce 96-well plate non-radioactive ELISA PTK assay method may be adapted to the Cellular Mimetic assay conditions for initial src screening of the 96-well plate combinatorial libraries. This high throughput assay utilizes the same RR-SRC peptide substrate, except that it is biotinylated so that it can be attached to the
25 NeutrAvidin-coated wells in their commercial 96-well plates. This high throughput inhibition assay can be run by incubating src with the RR-SRC substrate prebound to the wells followed by adding their anti-phosphotyrosine antibody (PY20)-horseradish peroxidase (HRP) conjugate and their HRP substrate to quantitate the level of
30 phospho-RR-SRC produced via measuring the level of HRP product with a 96-well plate UV reader. Standard low throughput P³²-ATP radioactive assays have been used, but a 96-well plate format is preferred, especially with a non-radioactive assay if possible. As very potent src inhibitors are developed, a panel of protein kinase assays

could be set up with up to ca. 6 commercially available protein kinases (mostly PTKs), using the Cellular Mimetic protein kinase assay conditions, and test these inhibitors across the panel to obtain an initial assesement of specificity. A more complete specificity assessment, involving the full ca. 2,000 protein kinases, will need
5 to be conducted in cell culture and in vivo through additional collaborations at the appropriate time.

Active src inhibitors can be studied in a set of side-by-side cell-based assays using normal rat kidney (NRK) cells and a temperature-sensitive pp60^{v-src} tranformant of this cell line (LA25). The LA25 transformant engages in anchorage- and serum-
10 independent growth at the “permissive” temperature of 33°C due to activation of pp60^{v-src} but not at the “non-permissive” temperature of 40°C at which pp60^{v-src} is not activated (Li et al., 1996). The use of this pair of closely related cell lines for testing the src inhibitors at both the permissive and non-permissive temperatures allows one to determine if a given src inhibitor is blocking cell growth due to specific blockade
15 of the src signalling pathway, by a different mechanism or by a general cytotoxic effect. Results from initial testing of the non-peptide src inhibitor **43**-meta (Table V) in this pair of cell lines are shown in Figure 14.


As shown in this graph the growth of the LA25 cells at the permissive temperature of 33°C is inhibited by ca. 50% at a 25 µM concentration of **43**-meta
20 relative to the LA25 cell growth at the non-permissive 40°C as a control. The lack of cell toxicity of **43**-meta is evidenced by the fact that as its concentration is increased up to 400 µM, the basal growth of the NRK non-transformed cells, the LA25 cells at the non-permissive 40°C and the LA20 cells at the permissive temperature of 33°C (but with pp60^{v-src} fully inhibited by **43**-meta) not only does not decrease but actually
25 increases somewhat (presumably due to a non-src related activity of this compound). Since the **43**-meta solutions were prepared with a low concentration of DMSO for solubilization a DMSO control was also run at the same concentration. A more complete dose/response curve centered around 25 µM will be run.

In another embodiment, the present invention provides a method of inhibiting
30 a protein kinase. The protein kinase is contacted with a compound having a first module which has a functionality for binding to catalytic residues of the protein

kinase and a second module which provides a non-peptide scaffold. The combination of the first and second modules inhibits the protein kinase activity.

A preferred non-peptide protein tyrosine kinase inhibitor provided by the present invention has the following formula:

5




10 wherein R1 is H or OH, R2 is H or OH, R3 is OH or H, and R4 is CH₃, CH₂(CH₃)R, or CH₂(CH₃)S, R5 is OCH₃, H, or OH, R6 is OCH₃, F, H, or OH, and R7 is OCH₃, H, OH, CO₂H, CO₂CH₃, CH₂CO₂H, or CH₂CO₂CH₃. In a more preferred embodiment, the non-peptide protein tyrosine kinase inhibitor inhibits the activity of pp60^{c-src} tyrosine kinase.

15

Another preferred non-peptide protein tyrosine kinase inhibitor has the following formula:

20




25

where R1 is OH or H, R2 is OH or H, R3 is OH or H, R4 is OH or H, R5 is OH, OMe, or H, R6 is OH, OMe, or H, R7 is OH, OMe, or H, and X is 0 or 1. In a more preferred embodiment, the non-peptide protein tyrosine kinase inhibitor has the above structure and R1 is OH, R2 is OH, R3 is H, R4 is H, R5 is OMe, R6 is H, R7 is H, and X is 1.

Yet another preferred non-peptide protein tyrosine kinase has the formula:

30



The present invention further provides a method of treating a condition, responsive to a protein kinase inhibitor, in a patient. An effective dose of a protein kinase inhibitor is administered to a patient. The protein kinase inhibitor has a first module having a functionality for binding to catalytic residues of the protein kinase and a second module which provides a non-peptide scaffold, where the combination of the first and second modules inhibits protein kinase activity.


Finally, promising src inhibitors can be screened in primary human tumor tissue assays, particularly to look for synergy with other known anti-cancer drugs.

EXAMPLES

Example 1 - Design, Synthesis and Activity of Non-ATP Competitive Hydroxynaphthalene Derivative Inhibitors of pp60^{c-Src} Tyrosine Kinase

The crystal structure of the autoinhibited human IRTK catalytic domain (Hubbard et al., 1994) was used to carry out qualitative molecular modeling studies (SYBYLTM, 6.4, Tripos Inc., St. Louis) wherein a naphthalene ring was superimposed upon the IRTK Tyr 1,162. The IRTK region containing Tyr 1,162 folds back into the active site, with Tyr 1,162 positioned analogous to a phosphorylatable Tyr in a peptide substrate, thereby autoinhibiting the tyrosine kinase. This superimposition indicated that an amide carbonyl should be placed at the 2-position (Scheme 1) of the

Scheme 1



naphthalene ring to mimic the Tyr 1,162 carbonyl and a hydroxyl group should be positioned at the 6-position to mimic the Tyr 1,162 hydroxyl group. These modeling studies also indicated that a hydroxyl group at the 3-position could mimic the Tyr 1,162 NH.

In order to test these design concepts experimentally, the 2-position carbonyl group was appended as either a methyl ester or as a series of amides (Table 6). The hydroxy N-phenyl (X=0) and N-benzyl (X=1) amides were chosen based upon the increase in pp60^{c-src} inhibitor potency observed with iminochromene analogs


5 containing appended hydroxy N-phenyl amide side-chains (Huang et al., 1995). Analogs wherein the 6-hydroxyl group was either deleted or moved were also prepared to determine if a drop in potency occurs as predicted from the modeling studies.

The series of 2-carbonyl-3,5-dihydroxy naphthalene inhibitors (**1a**, **2a-2d**, **2i-2l**, **2o-2p**) and 2-carbonyl-3,7-dihydroxy naphthalene inhibitors (**1c**, **2t-2u**) were synthesized from commercially available (Aldrich) 3,5-dihydroxy-2-naphthoic acid and 3,7-dihydroxy-2-naphthoic acid, respectively. The methyl esters **1a** and **1c** were obtained by refluxing the respective acid starting materials for 48h in methanol pre-saturated with HCl gas. The amides (**2a-2d**, **2i-2l**, **2o-2p**, **2t-2u**) were synthesized by
10 coupling the respective carboxylic acid with commercially available (Aldrich or Lancaster) amines using one of two methods. The first method utilized the NBS/PPh₃ methodology as described by Froyen (Froyen, 1997). The second method utilized IIDQ (Aldrich) as the coupling reagent. The carboxylic acid was first reacted with 1.0 eq. IIDQ in anhydrous DMF at room temperature for 24h. The respective amine (2.0
15 eq.) was then added neat and the reaction was heated to 80°C for 2-6 hours. After aqueous workup, purification was achieved by silica gel chromatography and precipitation from CH₂Cl₂/hexane, followed by preparative C-18 RP-HPLC (CH₃CN/H₂O), if necessary. The benzyl amines were commercially available only as their corresponding hydroxyl protected methyl ethers. Consequently, after amide
20 formation, the hydroxyl groups were deprotected by treatment with 6 eq. BBr₃ in DCM for 1 minute at -78°C followed by 1 hour at room temperature.

Table 6 Footnotes:

- ^a The previously described assay procedure (Lai et al., 1998) was used with the following assay components, final concentrations and conditions: 50.0 mM MOPS, 4.02 mM MgCl₂, 6.00 mM K₃citrate (used as a Mg²⁺ buffer to stabilize the *free* Mg²⁺ at 0.5 mM), 99.0 mM KCl, 10.0 mM 2-mercaptoethanol, 198 μM ATP, 19.8 μM ADP, 10 U full length human purified recombinant pp60^{c-src} (Upstate Biotechnology Inc.), 2.00 mM RR-SRC, 4.0 % DMSO, pH 7.2, 37°C. These overall assay conditions have been shown (Choi, 1999) to reproduce the intracellular conditions of pH, temp., *free* Mg²⁺ (0.5 mM), ionic strength, osmolality, ATP/ADP and reduction potential.
- ^b All new compounds were characterized by proton NMR, EI or FAB(+) MS and are pure by TLC.
- ^c N/A = Not applicable, n.t. = Not tested.
- ^d ATP-competitive.

The series of 2-carbonyl, 3,6-dihydroxy naphthalene inhibitors (**1b**, **2e-2h**, **2m-2n**, **2q-2s**) were synthesized from 3,6-dihydroxy-2-naphthoic acid **6** using the methods described above. The synthesis of intermediate **6** that was developed is shown in Scheme 2 beginning with commercially available 2,7-dihydroxynaphthalene **3** (Aldrich).



Compound **1d** was synthesized from 3-amino-2-naphthoic acid (Aldrich) by reaction with TMS-diazomethane in DCM at room temperature. Compound **2v** was synthesized from 6-hydroxy-2-naphthoic acid (Aldrich) using the amidation method described by Froyen (Froyen, 1997).

Kinase assay conditions have been shown to influence the measured inhibitory activity (Lawrence et al., 1998). Consequently, in order to accurately determine the relative potency of the newly designed class of pp60^{c-src} inhibitors, the inhibitory activity of four previously published, non-ATP competitive PTK inhibitors, was also tested. Piceatannol, ST-638, and Tyrphostin A47 were chosen because they are commercially available (Sigma or Calbiochem), and are representative of the spectrum of known non-ATP competitive PTK inhibitors. Emodin (Calbiochem) is ATP-competitive when analyzed with the tyrosine kinase p56^{lck}. Previously, iminochromene 9TA was the most potent non-ATP competitive pp60^{c-src} inhibitor reported (Huang et al., 1995). Since iminochromene 9TA was not commercially available, it was synthesized using a novel route by converting 3-Aminophenol to the corresponding TBDMS ether (1.1 eq. TBDMS-Cl, 1.1 eq. DIEA, 5 mol% DMAP, DMF, 24 h, rt, 71%). The resulting aniline was coupled using 2.0 eq. of cyanoacetic acid (1.1 eq. EDCI, 1.1 eq. TEA, DMF, 18 h, 75°C, 70%). Condensation of the resulting amide with 1.2 eq. of 2,3-dihydroxybenzaldehyde (cat. piperidine, abs. EtOH, 2 h, 60°C) followed by deprotection (1.1 eq. TBAF, THF, 15 m, 43% overall) gave iminochromene 9TA with satisfactory elemental, FAB(+)-MS and ¹H NMR analysis after purification by flash chromatography (10:1, DCM:MeOH).

The inhibitory activities shown in Table 6 for compounds **1a-d** and **2a-2v** were determined using purified, full length, human recombinant pp60^{c-src}. Due to the number of compounds tested, and the associated cost, their rank order potencies were first determined at a constant inhibitor concentration (100 μM). As predicted by the modeling studies, based upon analogy to the IRTK Tyr 1,162 hydroxyl group, a preference for positioning the naphthalene hydroxyl group on carbon 6 vs. 5 or 7 was observed in both the ester (**1b**, 47% vs. **1a**, 5% & **1c**, 19%) and amide (e.g. **2f**, 89% vs. **2b**, 51% & **2t**, 68%) series. The prediction that attaching a hydroxyl group at naphthalene carbon 3 (mimicking the Tyr 1,162 NH) would improve potency was also confirmed (**2f**, 89% vs. **2v**, 45%). Finally, the prediction that extending the inhibitor as an amide at the 2 position (mimicking the peptide bond) could further improve potency was confirmed as well (e.g. **2f**, 89% vs. **1b**, 47%).

The data provided in Table 6 demonstrate that moving the hydroxyl group from the optimal 6 position to the adjacent naphthalene carbon 5 results in a different structure activity profile with regard to the optimal concurrent positioning of the hydroxyl group(s) in the amide side chain (e.g. **2f/2g** vs. **2b/2c**). Also of note is the replacement of the amide side chain hydroxyl group with a corresponding methoxy group in compounds **2i-2n**. In the case of the N-phenyl amides (**2i-2j**), their activity, relative to the corresponding hydroxy amides (**2b-2c**), was not reduced as significantly as in the case of the N-benzyl amides (**2k-2n** vs. **2o-2q, 2s**). This suggests that in the benzyl derivatives, the amide side chain hydroxyl groups either interact with the enzyme as hydrogen bond donors, or the methoxy groups are too large to fit in the binding site.

A more quantitative analysis of the selectivity for positioning a hydroxyl group on carbon 6 vs. 5 is provided by comparing the IC_{50} 's of **2f** (16 μ M) vs. **2b** (150 μ M), respectively. These results also confirm that a drop in % inhibition from ca. 90% to ca. 50% represents an order of magnitude difference in potency, as expected. Similarly, a drop in % inhibition from ca. 50% to 10% would represent another order of magnitude difference in potency.

A direct comparison of the most potent inhibitor from this series, compound **2f**, with the five previously reported PTK inhibitors shown in Table 6 demonstrates that, under these assay conditions, **2f** is more potent by one to two orders of magnitude. Interestingly, iminochromene 9TA was previously reported (Huang et al., 1995) to have an IC_{50} of 118 nM against pp60^{c-src}, and was the most potent known non-ATP competitive pp60^{c-src} inhibitor, but under the current assay conditions only a 30% inhibition at 100 μ M was observed. These results re-emphasize (Lawrence et al., 1998) the importance of comparing protein kinase inhibitors under identical assay conditions.

A goal of these studies was to obtain non-peptide pp60^{c-src} inhibitors which do not compete with ATP. Consequently the % inhibition of pp60^{c-src} by **2f** and **2b** at constant inhibitor concentrations was monitored as a function of increasing [ATP] up to a cellular mimetic 1 mM level. Since the [ATP] had little effect on the %


inhibition, both **2f** and **2b** are non-competitive inhibitors with respect to ATP. The % inhibition was measured using ATP concentrations of 200, 500 & 1,000 μ M while holding the inhibitor concentration constant. If the inhibitor is directly competing with ATP, then this 5-fold overall increase in [ATP] is equivalent to decreasing the inhibitor concentration 5-fold in terms of the effect on % inhibition. Consequently the % inhibition should decrease to the value observed in the IC_{50} dose-response curve (obtained with 200 μ M ATP) for 1/5 of the set inhibitor concentration used in this experiment if direct competition with ATP is occurring. For inhibitor **2f** (set at 25 μ M) a 62% (+/-5), 54% (+/-3) and 50% (+/-1) inhibition at 200 μ M, 500 μ M and 1,000 μ M ATP, respectively, was obtained whereas the level of inhibition should have dropped to ca. 20% at 1,000 μ M ATP if direct competition with ATP were occurring. Similarly, for inhibitor **2b** (set at 300 μ M) an 84% (+/-1), 81% (+/-1) and 77% (+/-2) inhibition at 200 μ M, 500 μ M and 1,000 μ M ATP, respectively, was obtained. The high cost of many kinases has stimulated other researchers to monitor inhibitor potency as a function of increasing [ATP] for the same purpose (Saperstein et al., 1989; Burke et al., 1993; Davis et al., 1989; Davis et al., 1992; Faltynek et al., 1995; and Sawutz et al., 1996).

In summary, structure-based design has produced a series of hydroxynaphthalene pp60^{c-src} non-peptide inhibitors that do not compete with ATP. Results with compounds from this series in cell-based assays, as well as detailed kinetic studies under various assay conditions, will be reported in due course. An extension of these design concepts from the naphthalene scaffold to an indole scaffold is reported in the following paper.

Example 2 - Design, Synthesis and Activity of Non-ATP Competitive Hydroxyindole Derivative Inhibitors of pp60^{c-Src} Tyrosine Kinase

In the preceding example, the structure-based design of a series of pp60^{c-src} inhibitors utilizing a naphthalene scaffold is described. These compounds were designed to bind in the peptide substrate site because of the potential for greater selectivity and efficacy in a cellular environment relative to the alternative ATP


Scheme 1



substrate site. This example presents an extension of these design concepts to a series of pp60^{c-src} inhibitors based upon an indole scaffold. Once again the crystal structure of the autoinhibited insulin receptor PTK (IRTK) was used to carry out qualitative molecular modeling studies, except in this case an indole ring was superimposed upon the IRTK Tyr 1,162. This superimposition indicated that the indole NH can mimic the Tyr 1,162 NH, that a carbonyl should be placed at the 2-position, and a hydroxyl group at the 5 position to mimic the Tyr 1,162 carbonyl and OH, respectively (Scheme 1). The conceptual cyclization of Tyr 1,162 to the smaller 5-membered ring of an indole illustrated in Scheme 1, relative to a 6-membered ring in the case of the naphthalene scaffold (Karni et al., 1999), results in a movement of the optimal positioning of the OH from carbon 6 in the naphthalene scaffold to carbon 5 in the indole scaffold.

The indole amide derivatives containing hydroxy phenyl/benzyl side chains **2d-f**, **2j-l** (Table 7), respectively, were selected based upon the increase in pp60^{c-src} inhibitor potency observed for the analogous naphthalene-based hydroxy phenyl amides reported in the previous example. The corresponding methyl ethers **2a-c**, **g-i**, **v** are precursors in the synthesis. The additional analogs shown in Table 7 were prepared to begin expanding the range of side chains beyond the hydroxy/methoxy groups that have now been extensively probed with both the indole and naphthalene scaffolds.


The indole amides containing only hydroxy or methoxy side chains were synthesized as illustrated:



The 2-indolecarboxylic acid derivative, the methoxyphenyl amine (1.1 eq, Aldrich, Lancaster or Fluka), and the coupling reagent PyBOP (benzotriazol-1-yloxy)tripyrrolidino-phosphonium-hexafluorophosphate) (1 eq, Fluka) were dissolved in anhydrous DMF. The solution was cooled to 0°C under argon and then diisopropylethylamine (DIEA, 3 eq) was added. The reaction was stirred at 0°C for 1m followed by 1 hour at room temperature. After workup the residue was purified by silica gel chromatography.

The methyl ethers were cleaved with boron tribromide (1 M in DCM, Aldrich) when desired. The indole amide methyl ether was suspended in dry DCM and cooled to -78°C under argon. One equivalent of BBr₃ was added for each heteroatom in the starting material plus one excess equivalent. The resulting dark red solution was stirred at -78° for 30m and then at room temperature for 1-2 hours. The reaction was quenched with water (10 minutes) before workup.

Table 7: pp60^{c-src} inhibitory activity of hydroxyindole derivatives.^{a,b,c}



Compd	R1	R2	R3	R4	R5	R6	R7	% Inhibition at 100 μ M (std. dev.)
1a	H	OH	H	CH ₃	N/A	N/A	N/A	40 (+/-5) [at 500 μ M]
1b	H	OH	OH	CH ₂ CH ₃	N/A	N/A	N/A	28 (+/-3)
2a	H	OH	H	--	OCH ₃	H	H	3 (+/-1)
2b	H	OH	H	--	H	OCH ₃	H	21 (+/-2)
2c	H	OH	H	--	H	H	OCH ₃	39 (+/-9)
2d	H	OH	H	--	OH	H	H	43 (+/-1)
2e	H	OH	H	--	H	OH	H	30 (+/-6)
2f	H	OH	H	--	H	H	OH	45 (+/-3)
2g	H	OH	H	CH ₂	OCH ₃	H	H	21 (+/-5)
2h	H	OH	H	CH ₂	H	OCH ₃	H	7 (+/-6)
2i	H	OH	H	CH ₂	H	H	OCH ₃	18(+/-4)
2j	H	OH	H	CH ₂	OH	H	H	24(+/-3)
2k	H	OH	H	CH ₂	H	OH	H	74(+/-2) [IC ₅₀ = 38 μ M]
2l	H	OH	H	CH ₂	H	H	OH	54(+/-2)
2m	H	OH	H	CH ₂ CH ₂	H	H	OH	21(+/-7)
2n	H	OH	H	CH ₂	H	H	CO ₂ H	not active
2o	H	OH	H	CH ₂	H	H	CO ₂ CH ₃	11(+/-4)
2p	H	OH	H	--	H	H	CH ₂ CO ₂ H	7(+/-6)
2q	H	OH	H	--	H	H	CH ₂ CO ₂ CH ₃	32(+/-7)
2r	H	OH	H	--	H	F	H	21(+/-7)
2s	H	OH	H	CH ₂	H	F	H	57(+/-6)
2t	H	OH	OH	CH ₂	H	OH	H	26(+/-2)
2u	H	H	OH	CH ₂	H	OH	H	56(+/-6)
2v	H	H	H	CH ₂	H	H	OCH ₃	4(+/-4)
2w	H	H	H	CH ₂	H	H	OH	36(+/-4)
2x	OH	H	H	CH ₂	H	OH	H	60 (+/-3)
2y	H	OH	H	CH(CH ₃) R	H	OH	H	15(+/-3)
2z	H	OH	H	CH(CH ₃) S	H	OH	H	13(+/-7)

^a All compounds were tested as described in the preceding paper.⁵

^b All compounds were characterized by proton NMR, FAB(+) MS and are pure by TLC.

^c N/A = Not applicable.

Using this synthetic route, the series of 5-hydroxyindole amide inhibitors **2a-m,y,z** were prepared from 5-hydroxy-2-indolecarboxylic acid. The 4- and 6-hydroxyindole amides (**2x,u**, respectively) were synthesized from methyl 4-methoxy-

2-indolecarboxylate and methyl 6-methoxy-2-indolecarboxylate, respectively. The 5,6-dihydroxyindole amide **2t** was prepared from ethyl 5,6-dimethoxyindole-2-carboxylate. Sonication of the esters in 1 N NaOH for 1h provided the corresponding carboxylic acids for coupling. The des-hydroxy indole amides **2v,w** were synthesized from indole-2-carboxylic acid. All of the indole starting materials were commercially available (Aldrich or Lancaster).

The fluoro inhibitors **2r,s** were likewise prepared from the corresponding fluorophenyl amines (Aldrich). The inhibitors containing esters or carboxylic acids on the amide side chain, **2n-q**, were prepared from the corresponding amino carboxylic acids (Aldrich). The side chain carboxylic acid was first protected as a methyl ester (anh. MeOH pre-saturated with HCl, reflux, 1d), followed by PyBOP coupling (as above), then saponification back to the carboxylic acid when desired.

The methyl ester **1a** was prepared by refluxing a solution of the carboxylic acid overnight in anhydrous methanol pre-saturated with HCl gas. The ethyl ester **1b** was prepared by BBr₃ deprotection of ethyl 5,6-dimethoxyindole-2-carboxylate as above. All of the inhibitors listed in Table 7 were purified by silica gel chromatography.

As in Marsilje 2000, the rank order activity of this series of pp60^{c-src} inhibitors was first determined at a constant inhibitor concentration (Table 7). The same inhibitor concentration (100 μM) was used for the current indole series of inhibitors, the previous naphthalene series of inhibitors, and five non-ATP competitive literature PTK inhibitors (see preceding paper). This allowed an efficient rank order comparison of 59 compounds in total under identical assay conditions.

The modeling studies predicted that a hydroxy group at carbon 5 of the indole scaffold would be optimal. Comparison of the 5-hydroxy indole inhibitor **2k** (74%) with the analogous 6-hydroxy indole inhibitor **2u** (56%) and 4-hydroxy indole inhibitor **2x** (60%) confirms this prediction, although the preference is not strong. The prediction that a hydroxy group at carbon 5 will improve the activity (relative to no hydroxy group) is confirmed by comparing the 5-hydroxy indole inhibitor **2l** (54%) with the corresponding des-hydroxy inhibitor **2w** (36%).


Extending the indole inhibitors as aryl amides at carbon 2 improved potency, as expected based upon the previous naphthalene inhibitors. For example, the meta-hydroxybenzyl amide indole **2k** gives 74% inhibition at 100 μ M whereas the analogous methyl ester **1a** gives only 40% inhibition at 500 μ M. Interestingly, comparing the 5,6-dihydroxy ethyl ester **1b** (28%) to the corresponding aryl amide **2t** (26%) shows that the simultaneous presence of the second hydroxy at carbon 6 prevents the potency enhancement normally provided by the otherwise preferred meta-hydroxybenzyl amide side chain. This amide side chain was the best of the current series when the 5-hydroxyl group is present alone (**2k**, 74%) and still gave good inhibition when a 6-hydroxy group was present alone (**2u**, 56%). Also, the simultaneous presence of two hydroxy groups at carbons 5 & 6 seems well tolerated in the absence of an amide side chain (**1b** vs. **1a** & **2e**). This data suggests that a change in the binding orientation of the indole scaffold may have occurred due to the presence of the second hydroxy group and that a different amide side chain may now be preferred. The optimal combination of side chains at carbons 4-7 (including functional group replacements for hydroxy groups (Lai et al., 1999)) and amide side chains is currently under investigation.

In general, the indole scaffold structure-activity-relationships (“SARs”) revealed by the data in Table 7 parallels that reported in the preceding paper for the naphthalene scaffold. In both cases positioning a hydroxy group on the scaffold analogous to the Tyr 1,162 OH, as identified by modeling studies, provided the highest potency. Moving this hydroxy group to one of the adjacent carbons reduced the potency, but not dramatically, in both cases. Extending both scaffolds with aryl amides at the position identified by the modeling studies to mimic the Tyr 1,162 peptide bond improved the potency. With both scaffolds, substitution of a methoxy group for the hydroxy groups on the amide side chain usually reduced potency, and did so to a greater extent with the longer benzylamide side chain (e.g. **2k**, 74% vs. **2h**, 7% compared to **2e**, 30% vs. **2b**, 21%). The major difference in the SARs for these two scaffolds is that the 5-hydroxyindole scaffold prefers the longer m-hydroxybenzyl amide side chain (**2k**, 74% vs. **2e**, 30%) whereas the analogous 3,6-dihydroxynaphthalene scaffold prefers the shorter amide side chain derived from m-

hydroxyaniline. The 5-hydroxyindole scaffold showed essentially no preference for the position of the hydroxyl group on the shorter amide side chain (**2d-f**) whereas with the longer hydroxybenzyl amide side chain a significant preference for the meta position was observed (**2j-l**). In the case of the 3,6-dihydroxynaphthalene scaffold the opposite was observed.

Additional molecular modeling studies were carried out to further probe the preference for a longer amide side chain with the indole scaffold. The most active naphthalene inhibitor **3** from the previous report was used as a template upon which the analogous indole inhibitor **2e** and the homologated indole inhibitor **2k** were superimposed. The three most important side chain functional groups in naphthalene inhibitor **3** are considered to be the 6-hydroxy group (H-bond donor and acceptor), the

Scheme 3



hydrogen from the 3-hydroxy group (H-bond donor), and the side chain hydroxy group (H-bond acceptor) based upon the rational design and SAR for both series of inhibitors. This three point pharmacophore model is identified in both series by asterisks in Scheme 3.

The “multifit”, energy minimization and “fit atoms” facilities within SYBYLTM (6.4, Tripos, St. Louis) were used in sequence to superimpose **2e** and **2k** onto **3**. This overall fitting process was carried out with spring constants (multifit) and weights (fit atoms) chosen such that the highest emphasis was on optimally superimposing the scaffold pharmacophore O’s and H’s (100), followed by the side chain O’s (10) and then the intervening amide bond (1). The “multifit” process adjusted the conformations for maximum pharmacophore fit, the subsequent minimization produced the nearest local minimum energy conformations and finally the “fit atoms” process produced the best pharmacophore superimposition of these

minimized conformations. As expected, the scaffold pharmacophore O's and H's of both **2e** and **2k** superimposed closely and similarly upon the corresponding atoms in **3** (all within ca. 0.50 Å°). However, the side chain pharmacophore O's of **2e** and **2k** differed significantly in their superimposition on the corresponding O of **3**, with
5 displacements of 1.8 Å° vs. only 0.08 Å° respectively. This close fit of the three key pharmacophore sites between **2k** and **3** provides a rationalization for their potency differing by only a factor of 2.4 (IC₅₀'s 38 µM vs. 16 µM, respectively).

Extending the amide side chain by another carbon atom reduced the activity (**2m**, 21% vs. **2l**, 54%). Adding a methyl group to the benzylic carbon of **2k**, in either
10 stereochemistry, greatly reduced the activity (**2y**, 15% & **2z**, 13% vs. **2k**, 74%). Replacing the side chain hydroxy group (in the para position) with a carboxylate anion (**2n**, 0% vs. **2l**, 54% and **2p**, 7% vs. **2f**, 45%) reduced the activity whereas the corresponding methyl esters (**2o**, 11% & **2q**, 32%, respectively) showed a smaller loss of potency. Importantly, replacing the side chain hydroxy group with a fluorine
15 maintained much of the potency (**2s**, 57% vs. **2k**, 74% and **2r**, 21% vs. **2e**, 30%). Consequently, the fluoro analog **2s** has only one hydroxy group left for potential Phase II metabolism (e.g. glucuronide formation), and this remaining hydroxy group is a current target for replacement (Lai et al., 1998).


Using the same method as in the preceding example (Marsilje2000), the most
20 potent inhibitor from the current indole series (**2k**) was analyzed for ATP competition by monitoring the % inhibition at increasing [ATP] while holding the inhibitor concentration constant. Since the [ATP] had little effect on the % inhibition (The % inhibition was 46% and 41% with **2k** at 45 µM and [ATP] at 200 µM or 1,000 µM, respectively.), **2k** is non-competitive with respect to ATP under these assay
25 conditions.

In summary, an indole scaffold has been designed, and an initial SAR carried out, for the development of non-ATP competitive pp60^{c-src} inhibitors. The potency of the best indole-based inhibitor from the current series was found to be close to that of the best naphthalene-based inhibitor. The % inhibition was 46% and 41% with **2k** at
30 45 µM and [ATP] at 200 µM or 1,000 µM, respectively.

Example 3 - Synthesis of Indole Derivative Protein Kinase Inhibitors

The following results show the synthesis and testing of indole derived protein kinase inhibitors. Four reaction schemes are provided and separately followed by experimental details for the preparation of the final product of each of these reaction schemes. These final products are examples of indole-base tyrosine kinase inhibitors wherein the synthesis with preferred R groups is illustrated (boronic acid, Scheme 1; OH, Scheme 2; an aliphatic amide extension, Scheme 3; and a phosphonic acid Scheme 4).

Scheme 1



Methyl 5-hydroxy-2-indolecarboxylate (1)

Dissolved 3.50 g 5-hydroxy-2-indolecarboxylic acid in anh. MeOH presaturated with HCl gas. Refluxed for 48 hours. Concentrated *in vacuo* and triturated with AcCN x3
5 to remove residual acid. Filtered through silica plug with EtOAc to remove baseline contamination. Recovered 4.32 g (quant. yield) TLC R_f = .78 (EtOAc) ¹H NMR (DMSO-d₆): 3.82 (s, 3H), 6.78 (d, J=8.8 Hz, 1H), 6.88 (s, 1H), 6.93 (s, 1H), 7.23 (d, J=8.8 Hz, 1H), 8.90 (s, 1H) 11.62 (s, 1H) FAB(+) MS m/e 191.9 (M+1)

10 **Methyl 5-[(trifluoromethyl)sulfonyloxy]indole-2-carboxylate (2)**

Added 150 ml anh. DCM to 3.24 g (17 mmol) methyl 5-hydroxy-2-indolecarboxylate (1) and 6.67 g (18.7 mm) n-phenyl trifluoromethane sulfonamide at 0°C. Added 2.6 ml triethylamine dropwise at which point clear yellow solution formed. Stirred at 0°C
15 *in vacuo* and purified through silica gel column (1/1 EtOAc/hexanes). Recovered 4.69 g (86%). TLC R_f = .63 (1/1 EtOAc/hexanes). HPLC R_f = 20.879 ¹H NMR (DMSO-d₆): 3.87 (s, 3H), 7.25 (s, 1H), 7.31 (d, J=9.2 Hz, 1H), 7.55 (d, J=9.2 Hz, 1H), 7.80 (s, 1H), 12.34 s, 1H) FAB(+) MS m/e 323.1 (M+1).

20 **Methyl 5-methylindole-2-carboxylate, 4,4,5,5-tetramethyl-1,3,2-dioxaborolanemethyl (3)**


500 mg 1.55 mmol methyl 5-[(trifluoromethyl)sulfonyloxy]indole-2-carboxylate (2), 37.9 mg (.05 mmol) PdCl₂ (dppf), 432 mg (1.7 mmol) bispinacolatodiboron, 454.8 mg (4.65 mmol) potassium acetate, and 25.7 mg (.05 mmol) dppf were added to a flask
25 and vacuum dried at 40°C for 2 hours. Added 20 ml anh dioxane and heated to 80°C overnight. Reaction turned black as Pd black precipitated out. Filtered off catalyst and ran silica plug to remove baseline impurities. TLC R_f = .51 (1/4 EtOAc/Hexane) Crude product was taken through to next reaction.

30 **Methyl 5-boronyl indole-2-carboxylate (4)**

391.2 mg (1.3 mmol) methyl 5-methylindole-2-carboxylate, 4,4,5,5-tetramethyl-1,3,2-dioxaborolanemethyl (3) was dissolved in EtOAc. 0.25ml (2.6 mmol) diethanolamine

was added, and the reaction was stirred at room temperature overnight. The white ppt which formed was filtered and sonicated in 1 N HCl. The resulting white ppt was filtered, dissolved in MeOH, and concentrated *in vacuo*. Recovered 36.6 mg (13 %). HPLC R_f = 13.912, ^1H NMR ($\text{DMSO-}d_6$): 3.85 (s, 3H), 7.15 s, (1H), 7.36 (d, J =8.4 Hz, 1H), 7.67 (d, J = 8.4 Hz, 1H), 7.87 (s, 1H), 8.14 (s, 1H), 11.91 (s, 1H).

Scheme 2



10

(5-hydroxyindol-2-yl)-N-[(3-methoxyphenyl)methyl]carboxamide (5)


Dissolved 2.00g (11.3 mmol) 5-hydroxy-2-indolecarboxylic acid, 1.6 ml (12.4 mmol) 3-methoxybenzylamine, and 5.87 g (11.3 mmol) PyBOP in 10 ml anhydrous DMF. Cooled to 0°C and added 5.9 ml (33.9 mmol) DIEA. Stirred for 5 min at 0°C and allowed to warm to room temperature for 1 hour. Recovered 2.83g (85% yield) TLC R_f = 0.34 (1/1 EtOAc / hexanes) ^1H NMR ($\text{DMSO-}d_6$): 3.70 (s, 3H), 4.43 (d, J = 4.4 Hz, 2H) 6.69 (d, J = 8.8 Hz, 1H), 6.78 (d, J = 7.7 Hz, 1H), 6.83 (s, 1H), 6.86 (s, 1H), 6.94 (s, 1H), 7.20 (m, 3H), 8.92 (t, J =4.4 Hz, 1H), 11.36 (s, 1H) FAB(+) MS m/e 297.3 ($M+1$)

20

(5-hydroxyindol-2-yl)-N-[(3-hydroxyphenyl)methyl]carboxamide (6)

Added 20 ml anh. DCM to 200 mg (0.67 mmol) (5-hydroxyindol-2-yl)-N-[(3-methoxyphenyl)methyl]carboxamide(**5**) and cooled to -78°C under argon. Added 4.0 ml (4.0 mmol, 6 eq) BBr₃. Held at -78°C for 5 min and warmed to rt. After 90 min at rt, quenched with H₂O and stirred for 10 min. Diluted rxn mix with EtOAc and washed with NaHCO₃ and brine. Dried organic layer over MgSO₄ and concentrated *in vacuo*. Ran through silica plug to remove baseline contamination. Recovered X mg. (80% yield.) TLC R_f=0.21 (1/1 EtOAc/hexanes). ¹H NMR (DMSO-d₆): 4.38 (d, J= 4.8 Hz, 2H), 6.59 (d, J=8.8 Hz, 1H), 6.71 (m, 3H) 6.83 (d, J=1.8 Hz, 1H), 6.94 (s, 1H), 7.08 (dd, J= 7.7 Hz, 1H), 7.19 (d, J=8.8 Hz, 1H), 8.84 (t, J=5.9Hz), 11.28, (s, 1H). FAB(+) MS m/e 283.2 (M+1)

Scheme 3




N-(1-carbamoyl-2-methylbutyl)(5-hydroxyindol-2-yl)carboxamide (7)

100 mg (0.56 mmol) 5-hydroxy-2-indolecarboxylic acid, 103.4 mg (0.62 mmol, 1.1 eq) L-isoleucinamide, and 291 mg (0.56 mmol, 1 eq) PyBOP were all dissolved in 1 ml anh DMF. The solution was cooled to 0° C and 0.3 ml (1.68 mmol, 3 eq) DIEA was added. The reaction mixture was stirred for 1 min at 0° C and at room temperature for 1 hour. The reaction was then diluted with EtOAc and washed with 1 N HCl x3 and sat'd NaHCO₃ x 3. The organic layer was dried over MgSO₄, and concentrated *in vacuo* to give 166.7 mg (91 % yield.) TLC R_f=0.08 (1/1 EtOAc/hexanes). ¹H NMR (DMSO-d₆): 0.83 (m, 6H), 1.15 (m, 2H), 1.68 (m, 1H), 1.83 (m, 1H), 4.29 (t, J=8.8 Hz, 1H), 6.69 (d, J=8.5 Hz, 1H), 6.83 (s, 1H), 7.01, (s,

1H), 7.06 (s, 1H), 7.19 (d, J=8.4 Hz, 1H), 7.48, (s, 1H), 8.00 (d, 9.2 Hz, 1H), 8.76 (s, 1H), 11.3, (s, 1H). FAB(+) MS m/e 290.1 (M+1)

Scheme 4

5



Methyl 5-dibenzylphosphorylindole-2-carboxylate (8)

200 mg (0.62 mmol) methyl 5-[(trifluoromethyl)sulfonyl]indole-2-carboxylate (2), 195.8 mg (.74 mmol, 1.2 eq) dibenzylphosphite, 0.14 ml (0.81 mmol, 1.3 eq) DIEA, and 35.7 mg (0.03 mmol, 5 mol %) Pd(PPh₃)₄ were all dissolved in anhydrous AcCN under argon. The reaction mixture was heated to 80°C overnight. The solvent was removed under reduced pressure, and the title compound was isolated by silica gel chromatography. 130 mg (50% yield). TLC R_f=0.28 (1/1 EtOAc/hexanes) ¹H NMR

(DMSO-d₆): 3.85 (s, 3H), 4.98-5.01 (m, 4H), 7.28-7.32 (m, 11H), 7.53-7.55 (m, 2H), 8.17 (d, J=14.6 Hz, 1H) ³¹P NMR (DMSO-d₆): 23.89.

Methyl 5-phosphonolindole-2-carboxylate

5 Methyl 5-dibenzylphosphorylindole-2-carboxylate (**8**) (125 mg) was dissolved in 10 ml MeOH. 20 mg Pd-C was added and the mixture was hydrogenated in a Parr apparatus overnight. Filtered off catalyst and removed solvent under reduced pressure. Obtained 72.5 mg (73% yield). TLC R_f = baseline in EtOAc. ¹H NMR (DMSO-d₆): 3.84 (s, 3H), 7.24 (s, 1H), 7.44-7.49 (m, 2H), 8.01 (d, J=14.3 Hz, 1H)
10 12.11 (s, 1H) ³¹P NMR (DMSO-d₆): 17.22.


The ester compounds in this example could be increased in potency by converting the ester to an amide and/or adding additional specificity elements.

15


Example 4 – Synthesis of Further Indole Derivative Protein Kinase Inhibitors

The synthesis of some further elaborated indole inhibitors is illustrated in below. These syntheses should result in compounds with greater potency against
20 pp60c-src and other tyrosine kinases. The methyl ester group can be subsequently converted into various amide derivatives to increase potency.


Scheme 1:



Scheme 2:



Scheme 3:



Example 5 – Toxicity of Src inhibitors

There is considerable recent literature support for targeting pp60^{c-src} (Src) as a broadly useful approach to cancer therapy without resulting in serious toxicity. For example, tumors that display enhanced EGF receptor PTK signaling, or overexpress the related Her-2/neu receptor, have constitutively activated Src and enhanced tumor invasiveness. Inhibition of Src in these cells induces growth arrest, triggers apoptosis, and reverses the transformed phenotype (Karni et al., 1999). It is known that abnormally elevated Src activity allows transformed cells to grow in an anchorage-independent fashion. This is apparently caused by the fact that extracellular matrix signaling elevates Src activity in the FAK/Src pathway, in a coordinated fashion with mitogenic signaling, and thereby blocks an apoptotic mechanism which would normally have been activated. Consequently FAK/Src inhibition in tumor cells may induce apoptosis because the apoptotic mechanism which would have normally become activated upon breaking free from the extracellular matrix would be induced (Hisano et al., 1997). Additionally, reduced VEGF mRNA expression was noted upon Src inhibition and tumors derived from these Src-inhibited cell lines showed reduced angiogenic development (Ellis et al., 1998).

The issue of potential toxicity of Src inhibition has been addressed with very promising results. For example, a knock-out of the Src gene in mice led to only one defect, namely osteoclasts that fail to form ruffled borders and consequently do not resorb bone. However, the osteoclast bone resorb function was rescued in these mice by inserting a kinase defective Src gene (Schwartzberg et al., 1997). This suggested that Src kinase activity can be inhibited *in vivo* without triggering the only known toxicity because the presence of the Src protein is apparently sufficient to recruit and activate other PTKs (which are essential for maintaining osteoclast function) in an osteoclast essential signaling complex.

Src has been proposed to be a “universal” target for cancer therapy since it has been found to be overactivated in a growing number of human tumors, in addition those noted above (Levitzki, 1996). The potential benefits of Src inhibition for cancer therapy appear to be four-fold based upon the cited, and additional, literature. They are: 1) Inhibition of uncontrolled cell growth caused by autocrine growth factor loop effects, etc. 2) Inhibition of metastasis due to triggering apoptosis upon breaking free

from the cell matrix. 3) Inhibition of tumor angiogenesis via reduced VEGF levels.
4) Low toxicity.

The initial non-peptide Src inhibitors have also shown very encouraging results in four different series of cell culture assays. 1) In the NIH 60-tumor cell panel assay, broad activity (as one would expect for a Src inhibitor) was seen against the tumor cell lines, including the prostate lines. For example, three of the inhibitors gave the following growth inhibition IC_{50} 's against the NIH prostate cancer cell lines: TOM 2-32 (PC-3, 15 μ M; DU-145, 38 μ M), TOM 2-47 (PC-3, 19 μ M), KLM 2-31 (PC-3, 39 μ M; DU-145, > 100 μ M). 2) In the v-Src transformed normal rat kidney cell line (LA25) TOM 2-47 & TOM 2-32 specifically blocked the v-Src induced cell growth without inhibiting the normal growth of the parent non-transformed cells. This result showed that the inhibitors do not affect normal cells but are effective in blocking Src induced cell transformation. 3) The Src inhibitors to the cancer drugs etoposide, taxol, doxorubicin and cisplatin in ovarian tumors from three different patients and an abdominal carcinoma from another patient. In all cases, the Src inhibitors were at least as effective, and typically more effective, than the known cancer drugs, with full efficacy seen at the lowest dose tested (3 μ M). As a representative example, a comparison of taxol and doxorubicin (they were more effective than etoposide & cisplatin in this particular tumor cell culture) with the three Src inhibitors mentioned above utilizing ovarian tumor cells from tumor N015 is shown in Figure 15A. 4) The Src inhibitors were also tested for inhibition of normal human fibroblast cell growth and found no inhibition of normal cell growth (both subconfluent and confluent; some enhanced growth was observed instead), indicating that these inhibitors are not toxic to normal cells even at a 10-fold higher concentration. An example of his data is given in Figure 15B.

Overall, the cell data obtained thus far shows what one might expect for Src inhibitors, i.e. broad activity against many cancer cell lines with little or no normal cell toxicity.

The preliminary Src inhibitors are lead structures from which it is possible to design more potent and selective inhibitors. In addition to utilizing the tyrosine kinase crystal structures, molecular modeling studies can be carried out with the natural product tyrosine kinase inhibitor damnacanthol (Faltynek et al., 1995) to

5

10

LITERATURE CITED

The following references which were cited herein, are hereby incorporated by reference into this application:

5

Ajay, Murcko, M. A. (1995) *Computational Methods to Predict Binding Free Energy in Ligand-Receptor Complexes*. J. Med. Chem., **38**, 4953-4967.

Alberts, B., Bray, D., Lewis, J., Raff, M., Roberts, K. & Watson, J. D. (1994)
10 *Molecular Biology Of The Cell*, 3rd ed., Garland Publishing, Inc., New York, pp 97, 508 & 667.

Alfaro-Lopez, J., Yuan, W., Phan, B. C., Kamath, J., Lou, Q., Lam, K. S., Hruby, V. J. (1998) *Discovery of a Novel Series of Potent and Selective Substrate-Based*
15 *Inhibitors of p60c-src Protein Tyrosine Kinase: Conformational and Topographical Constraints in Peptide Design*. J. Med. Chem., **41**, 2252-2260.

Backes, B. J., Virgilo, A. A., Ellman, J. A. (1996) *Activation Method to Prepare a Highly Reactive Acylsulfonamide "Safety-Catch" Linker for Solid-Phase Synthesis*. J.
20 Am. Chem. Soc., **118**, 3055-3056.

Baggio, R., Elbaum, D., Kanyo, Z. F., Carroll, P. J., Cavalli, C., Ash, D. E., Christianson, D. W. (1997) *Inhibition of Mn²⁺-Arginase by Borate Leads to the Design of a Transition State Analog Inhibitor, 2(S)-Amino-6-boronohexanoic Acid*. J.
25 Am. Chem. Soc., **119**, 8107-8108.

Barnekow, A.; Paul, E.; Scharf, M. (1987) *Expression of the c-src protooncogene in human skin tumors*. Cancer Res., **47**, 235-240.

Benson, W. H., Birge, W. J., Dorough, H. W. (1984) Environ. Toxicol. Chem., **3**,
30 209. Chem. Abstr. **101**:124626g.

Bhagwat, S. S., Gude, C. (1994) *N-Alkylation of indole ring using Mitsunobu reaction*. Tet. Lett., **35**, 1847-1850.

Bjorge, J. D., O'Connor, T. J., Fujita, D. J. (1996) *Activation of human pp60^{c-src}*. Biochemistry & Cell Biology, **74**, 477-484.

Bjelfman, C.; Hedborg, F.; Johansson, I.; Nordenskjold, M.; Pahlman, S. (1990) *Expression of the neuronal form of pp60c-src in neuroblastoma in relation to clinical stage and prognosis*. Cancer Res, **50**, 6908-6914.

Bohacek, R. S., McMartin, C., Guida, W. C. (1996) *The Art and Practice of Structure-Based Drug Design: A Molecular Modeling Perspective*. Medicinal Research Reviews, **16**, 3-50 (see p. 43).

Boyd, M. R., Paull, K. D. (1995) *Some practical considerations and applications for the National Cancer Institute in vitro anticancer drug discovery screen*. Drug Development Research, **34**, 91-109.

Brooks, S. P. J. & Storey, K. B. (1992) *Bound and Determined: A Computer Program for Making Buffers of Defined Ion Concentrations*. Analytical Biochemistry, **201**, 119-126.

Brown, D. (1997) *Future Pathways for Combinatorial Chemistry*. Molecular Diversity, **2**(4), 217-222.

Budde, R. J. A., McMurray, J. S., Saya, H., Gallick, G. E. & Levin, V. A. (1995) *Discovery, Development, and Testing of Substrates and Inhibitors of pp60^{c-src}*. International Journal of Pharmacognosy, **33**, 27-34.

Budde, R. J. A., Ke, S., Levin, V. A. (1994) *Activity of pp60c-src in 60 different cell lines derived from human tumors*. Cancer Biochem. Biophys., **14**, 171-175.

Burger, A. M., Kaur, G., Alley, M. C., Supko, J. G., Malspeis, L., Grever, M. R. & Sausville, E. A. (1995) *Tyrphostin AG17, [(3,5-Di-tert-butyl-4-hydroxybenzylidene)-malonitrile], inhibits cell growth by disrupting mitochondria*. Cancer Research, **55**, 2794-2799.

5

Burke, T. R.; Lim, B.; Marquez, V. E.; Li, Z-H.; Bolen, J. B.; Stefanova, I.; Horak, I. D. (1993) J. Med. Chem. **36**, 425.

Choi, S. (1999), Ph.D. Thesis SUNY at Buffalo, Buffalo, NY.

10

Cooper, C. M. (1990) *Oncogenes*. Jones and Bartlett Publishers, Boston, MA.

Coughlin, J. R. (1996) *Inorganic borates-chemistry, human exposure, and health and regulatory guidelines*. J. Trace Elements in Experimental Medicine, **9**, 137-151.

15

Courtneidge, S. A. (1994) *Protein tyrosine kinases, with emphasis on the Src family*. Seminars in Cancer Biology, **5**, 239-246.

Cox, S., Radzio-Andzelm, E. & Taylor, S. S. (1994) *Domain movements in protein kinases*. Current Opinion in Structural Biology, **4(6)**, 893-901.

20

Culver, B. D., Hubbard, S. A. (1996) *Inorganic boron health effects in humans- and aid to risk assessment and clinical judgment*. J. Trace Elements in Experimental Medicine, **9**, 175-184.

25

Davis, P. D.; Hill, C. H.; Keech, E.; Lawton, G.; Nixon, J. S.; Sedgwick, A. D.; Wadsworth, J.; Westmacott, D.; Wilkinson, S. E. (1989) FEBS Lett. **259(1)**, 61.

Davis, P. D.; Elliott, L. H.; Harris, W.; Hill, C. H.; Hurst, S. A.; Keech, E.; Kumar, M. K. H.; Lawton, G.; Nixon, J. S.; Wilkinson, S. E. (1992) J. Med. Chem. **35**, 994.

30

Ellis, L.M., Staley, C.A., Liu, W., Fleming, R.Y., Parikh, N.U., Bucana, C.D., & Gallick, G.E. (1998) *Down-regulation of vascular endothelial growth factor in a human colon carcinoma cell line transfected with an antisense expression vector specific for c-src.* Journal of Biological Chemistry **273** (2):1052-1057.

5

Ezquerro, J., Pedregal, C., Lamas, C., Barluenga, J., Perez, M., Garcia-Martin, M. A., Gonzalez, J. M. (1996) *Efficient reagents for the synthesis of 5-, 7-, and 5,7-substituted indoles starting from aromatic amines: scope and limitations.* J. Org. Chem., **61**, 5804-5812.

10

Faltynek, C., et al. (1995) *Damnacanthol is a highly potent, selective inhibitor of p56lck tyrosine kinase activity.* Biochemistry **34**, 12404-12410.

15

Faltynek, C. R.; Wang, S.; Miller, D.; Mauvais, P.; Gauvin, B.; Reid, J.; Xie, W.; Hoekstra, S.; Juniewicz, P.; Sarup, J.; Lehr, R.; Sawutz, D. G.; Murphy, D. J. (1995) *Enzyme Inhibition* **9**, 111.

20

Fanning, P.; Bulovas, K.; Saini, K.S.; Libertino, J.A.; Joyce, A.D.; Summerhayes, I.C. (1992) *Elevated expression of pp60^{c-src} in low grade human bladder carcinoma.* Cancer Research, **52**, 1457-1462.

Fredenhagen, A.; Mett, H.; Meyer, T.; Buchdunger, E.; Regenass, U.; Roggo, B. E.; Petersen, F. J. (1995) *Antibiotics* **48**, 1355.

25

Froyen, P. (1997) *Tetrahedron Lett.* **38**(30), 5359.

Fry, D. W., Kraker, A. J., McMichael, A., Ambroso, L. A., Nelson, J. M. Leopold, W. R., Connors, R. W. & Bridges, A. J. (1994) *A Specific Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase.* Science, **265**, 1093-1095.

30

Glass, D. B., Cheng, H.-C., Mende-Mueller, L., Reed, J. & Walsh, D. A. (1989) *Primary structure determinants essential for potent inhibition of cAMP-dependent*

protein kinase by inhibitory peptides corresponding to the active portion of the heat-stable inhibitor protein. J. Biol. Chem., 264, 8802-8810.

- Groundwater**, P. W., Solomons, K. R. H., Drewe, J. A. & Munawar, M. A. (1996)
5 *Protein Tyrosine Kinase Inhibitors. Progress in Medicinal Chemistry, 33, 233-329.*

Hanks, S. K. & Hunter, T. (1995) Protein kinases. 6. *The eukaryotic protein kinase superfamily: Kinase (catalytic) domain structure and classification. FASEB J., 9, 576-596.*

10

Hanke, J. H., Gardner, J. P., Dow, R. L., Changelian, P. S., Brisette, W. H.,
Weringer, E. J., Pollok, B. A. & Connelly, P. A. (1996) *Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor. J. Biol. Chem., 271, 695-701.*

15

Hisano, C., Nakano, S., Fujishima, H., Masumoto, N., Tatsumoto, T., & Niho. Y.
(1997) *src oncogene inhibits detachment-induced apoptosis through constitutive activation of p125FAK in HAG-1 human epithelial cells. Proc. Annu. Meet. Am. Assoc. Cancer Res. 38:A1925.*

20

Hsiao, G. K., Hangauer, D. G. (1998) *A Facile Synthesis of tert-Butyl 2-[(Benzyloxycarbonyl)amino]-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)propionate: An Orthogonally Protected Boronic Acid Analog of Aspartic Acid. Synthesis, 1043-1046.*

25

Hsu, C-Y., J., Jacoski, M. V., Maguire, M. P., Spada, A. P. & Zilberstein, A. (1992)
Inhibition Kinetics and Selectivity of the Tyrosine Kinase Inhibitor Erbstatin and a Pyridone-based Analog. Biochemical Pharmacology, 43, 241-2477.

30

Huang, C-K., Wu, F-Y., Ai, Y-X. (1995) *Polyhydroxylated 3-(N-phenyl) carbamoyl-2-iminochromene derivatives as potent inhibitors of tyrosine kinase p60c-src. Bioorg. & Med. Chem. Lett., 5, 2423-2428.*

Hubbard, S. R., Wei, L, Ellis, L, & Hendrickson, W. A. (1994) *Crystal structure of the tyrosine kinase domain of the human insulin receptor*, Nature, **372**, 746-754.

Hubbard, S. R. (1997) *Crystal structure of the activated insulin receptor tyrosine kinase in complex with peptide substrate and ATP analog*. The EMBO Journal, **16**, 5572-5581.

Hughes, R. L., Smith, I. C., Lawless, E. W. (1967) Production of the Boranes and Related Rearch, Holtzman R.T., Ed., Academic Press, New York, pp 291-294.

Hunter, T. (1987) *A thousand and one protein kinases*. Cell, **50**, 823-829.

Hunter, T. (1994) *1001 protein kinases redux-towards 2000*. Seminars in Cell Biology, **5**, 367-376.

Hunter, T. (1998) *The Croonian Lecture 1997. The phosphorylation of proteins on tyrosine: its role in cell growth and disease*. Philosophical Transactions of the Royal Society of London - Series B: Biological Sciences 353 (1368):583-605.

Hutchins, C., Greer, J. (1991) *Comparative modeling of proteins in the design of novel renin inhibitors*. Critical Reviews in Biochemistry & Molecular Biology, 26, 77-127.

Ishiyama, T., Murata, M., Miyaura, N. (1995) *Palladium(0)-catalyzed cross-coupling reaction of alkoxydiboron with haloarenes: A direct procedure for arylboronic esters*. J. Org. Chem., **60**, 7508-7510.

Ishiyama, T., Itoh, Y., Kitano, T., Miyaura, N. (1997) *Synthesis of arylboronates via the palladium(0)-catalyzed cross-coupling reaction of tetra(alkoxo)diborons with aryl triflates*. Tet. Lett., **38**, 3447-3450.

Karni, R., Jove R., & Levitzki A. (1999) *Inhibition of pp60c-src reduces Bcl-X expression and reverses the transformed phenotype of cells overexpressing EGF and HER-2 receptors.* Oncogene **18**(33): 4654-4662.

- 5 **Kelloff, G. J., Fay, J. R., Steele, V. E., Lubet, R. A., Boone, C. W., Crowell, J. A. (1996)** *Epidermal growth factor receptor tyrosine kinase inhibitors as potential cancer chemopreventatives.* Cancer Epidemiology, Biomarkers & Prevention, **5**, 657-666.

- 10 **Kettner, C. A., Shenvi, A. B. (1984)** *Inhibition of the Serine Proteases Leukocyte Elastase, Pancreatic Elastase, Cathepsin G, and Chymotrypsin by Peptide Boronic Acids.* J. Biol. Chem., **259**, 15106-15114.

- 15 **Kim, M. H., Lai, J. H. & Hangauer, D. G. (1994)** *Tetrapeptide tyrosine kinase inhibitors: Enantioselective synthesis of p-hydroxymethyl-L-phenylalanine, incorporation into a tetrapeptide, and subsequent elaboration into p-(R,S-hydroxyphosphonomethyl)-L-phenylalanine.* Int. J. Peptide Protein Res., **44**, 457-465.

- 20 **Kinder, D. H., Frank, S. K., Ames, M. M. (1990)** *Analogues of Carbamyl Aspartate as Inhibitors of Dihydroorotase: Preparation of Boronic Acid Transition-State Analogues and a Zinc Chelator Carbamylhomocysteine.* J. Med. Chem., **33**, 819-823.

Klein, G. (1990) *Multistep emancipation of tumors from growth control: can it be curbed in a single step?* BioEssays, **12**, 347-350.

25

Knighton, D. R., Cadena, D. L., Zheng, J., Ten Eyck, L. F., Taylor, S. S. & Sowadski, J. M. (1993) *Structural features that specify tyrosine activity deduced from homology modeling of the epidermal growth factor receptor.* Proc. Natl. Acad. Sci. U.S.A., **90**(11), 5001-5.

30

Kolibaba, K. S. & Druker, B. J. (1997) *Protein tyrosine kinases and cancer.* Biochimica et Biophysica Acta, **1333**: F217-F248.

Lai, J. H., Marsilje, T. M., Choi, S., Nair, S. A., Hangauer, D. G. (1998) *The design, synthesis and activity of pentapeptide pp60c-src inhibitors containing L-phosphotyrosine mimics.* J. Peptide Res., **51**, 271-281.

- 5 **Lai, J. H., Pham, H. & Hangauer, D. G. (1996)** *Synthesis of a Vicinal Tricarbonyl Amide Derivative of L-Phenylalanine.* J. Org. Chem., **61**, 1872-1874.

Lam, K. S. (1997) *Application of Combinatorial Library Methods in Cancer Research an Drug Discovery.* Anti-Cancer Drug Design, **12(3)**, 145-167.

10

Lawrence, D.S. & Niu, J. (1998) *Protein Kinase Inhibitors: The Tyrosine-Specific Protein Kinases.* Pharmacol. Ther., **77(2)**, 81-114.

15

Levitzki, A. (1996a) *Targeting signal transduction for disease therapy.* Current Opinion in Cell Biology, **8**, 239-244.

Levitzki, A. (1996b) *SRC as a target for anti-cancer drugs.* Anti-Cancer Drug Design, **11**, 175-182.

20

Levitzki, A.; Gazit, A. (1995) *Tyrosine Kinase Inhibition: An Approach to Drug Development.* Science, **267**, 1782-1788.

25

Li, H., Liu, T.F., Lazrak, A., Peracchia, C., Goldberg, G. S., Lampe, P. D., Johnson, R. G. (1996) *Properties and regulation of gap junctional hemichannels in the plasma membranes of cultured cells.* J. Cell. Biol., **134**, 1019-1030.

Loomis, W. D. & Durst, R. W. (1992) *Chemistry and biology of boron.* BioFactors, **3**, 229-239.

30

Lou, Q., Leftwich, M. E., McKay, T., Salmon, S. E., Rychetsky, L. & Lam, K. S. (1997) *Potent Pseudosubstrate-based Peptide Inhibitors for p60^{c-src} Protein Tyrosine Kinase.* Cancer Research, **57(10)**, 1877-1881.

Lou, Q., Leftwich, M. E. & Lam, K. S. (1996) *Identification of GIYWHHY as a Novel Peptide Substrate for Human p60c-src Protein Tyrosine Kinase*. Biorganic & Medicinal Chemistry, **4**, 677-682.

- 5 **Luttrell, D.K.**; Lee, A.; Lansing, T.J.; Crosby, R.M.; Jung, K.D.; Willard, D.; Luther, M.; Rodriguez, M.; Berman, J.; Gilmer, T.M. (1994) *Involvement of pp60^{c-src} with two major signaling pathways in human breast cancer*. Proc. Natl. Acad. Sci. USA, **91**, 83-87.

- 10 **Lynch, S.A.**; Brugge, J.S.; Fromowitz, F.; Glantz, L.; Wang, P.; Caruso, R.; Viola, M.V. (1993) *Increased expression of the src proto-oncogene in hairy cell leukemia and a subgroup of B-cell lymphomas*. Leukemia, **7**, 1416-1422.

- 15 **Madhusudan**, Trafny, E. A., , Xuong, N-H, Adams, J. A., Ten Eyck, L. F., Taylor, S. S. & Sowadski, J. M. (1994) *cAMP-dependent protein kinase: Crystallographic insights into substrate recognition and phosphotransfer*. Protein Science, **3**, 176-187.

- 20 **Mao, W. G.**, Irby, R., Coppola, D., Fu, L., Turner, J. (1997) *Activation of c-src by receptor tyrosine kinases in human colon cancer cells with high metastatic potential*. Oncogene, **15**, 3083-3090.

- 25 **Marsilje, T.H.**, Milkiewicz, K.L., & Hangauer, D.L. (2000) *The design, synthesis and activity of non-ATP competitive inhibitors of pp60c-src tyrosine kinase 1. Hydroxynaphthalene Derivatives*. Bioorganic and Medicinal Chemistry Letters, in press.

Marx, J. (1990) *Oncogenes evoke new cancer therapies*. Science, **249**, 1376-1378.

- 30 **National Cancer Institute** (1989) Survey of Compounds which have been tested for carcinogenic activity. NIH Publication No. 49-468, p. 16.

Matteson, D. S., Kandil, S. A., Soundararajan, R. (1990) *Synthesis of Asymmetrically Deuterated Glycerol and Dibenzylglyceraldehyde via Boronic Esters.* J. Am. Chem. Soc., **112**, 3964-3969.

5 **Matteson, D. S. (1988)** Acc. Chem. Res., **21**, 294-300.

Matteson, D. S., Kandil, A. A. (1987) *Conversion of α -halo boronic esters to inverted α -(methylsulfonyl)oxy boronic esters.* J. Org. Chem., **52**, 5121-5124.

10 **Matteson, D. S., Soloway, A. H., Tomlinson, D. W., Campbell, J. D., Nixon, G. A. (1964)** J. Med. Chem., **7**, 640.

Mazurenko, N.N.; Kogen, E.A.; Zborovskaya, I.B.; Kissel'ov, F.L. (1992)
Expression of pp60^{c-src} in human small cell and non-small cell lung carcinomas.
15 European J. of Cancer, **28**, 372-377.

Milkiewicz, K.; Marsilje, T.; Woodward Jr, R.; Bifulco Jr, N.; Hangauer, M.; Hangauer, D.G. (2000) *The design, synthesis and activity of non-ATP competitive inhibitors of pp60c-src tyrosine kinase 2. Hydroxyindole Derivatives.* Bioorganic and
20 Medicinal Chemistry Letters, in press.

Mohammadi, M., Schlessinger, J., Hubbard, S. R. (1996) *Structure of the FGF Receptor Tyrosine Kinase Domain Reveals a Novel Autoinhibitory Mechanism.* Cell, **86**, 577-587.

25

Mohammadi, M., McMahon, G., Li, S., Tang, C., Hirth, P., Yeh, B. K., Hubbard, S. R., Schlessinger, J. (1997) *Structures of the Tyrosine Kinase Domain of Fibroblast Growth Factor Receptor in Complex with Inhibitors.* Science, **276**, 955-960.

30 **Morin, C. (1994)** *The Chemistry of Boron Analogues of Biomolecules.* Tetrahedron, **50**, 12521-12569.

Murakami, Y., Otsuka, K. Wada, Y., Morikawa, A. (1990) *The partial oxidation of ethane over a B_2O_3 - Al_2O_3 catalyst*. Bull. Chem. Soc. Jpn., **63**, 340-346.

5 **Nair**, S. A., Kim, M. K., Warren, S. D., Choi, S., Songyang, Z., Cantley, L. C. & Hangauer, D. G. (1995). *Identification of Efficient Pentapeptide Substrates for the Tyrosine Kinase pp60^{c-src}*. J. Med. Chem., **38**, 4276-4283.

10 **Nair**, S. A., Lee, B. & Hangauer, D. G. (1995b). *Synthesis of Orthogonally Protected L-Homocysteine and L-2-Amino-4-phosphonobutanoic Acid From L-Homoserine*. Synthesis, **7**, 810-814.

Nielsen, F. H. (1997) *Boron in human and animal nutrition*. Plant & Soil, **193**, 199-208.

15 **Otsuka**, K., Uragami, Y., Hatano, M. (1992) *The partial oxidation of ethane to acetaldehyde*. Catalysis Today, **13**, 667-672.

20 **Parsons**, J. T. & Parsons, S. J. (1997) *Src family protein tyrosine kinases: cooperating with growth factor and adhesion signaling pathways*. Current Opinion in Cell Biology, **9**, 187-192.

Patrick, D. R. & Heimbrook, D. C. (1996) *Protein Kinase Inhibitors For The Treatment of Cancer*. Drug Discovery Today, **1**, 325-330.

25 **Pavia**, M. R., Cohen, M. P., Dilley, G. J., Dubuc, G. R., Durgin, T. L., Forman, F. W., Hediger, M. E., Milot, G., Powers, T. S., Sucholeiki, I., Zhou, S. & Hangauer, D. G. (1996) *The Design and Synthesis of Substituted Biphenyl Libraries*. Biorganic & Medicinal Chemistry, **4**, 659-666.

30 **Posner**, I., Engel, M., Gazit, A. & Levitzki, A. (1994) *Kinetics of Inhibition by Tyrphostins of the Tyrosine Kinase Activity of the Epidermal Growth Factor Receptor and Analysis by a New Computer Program*. Molecular Pharmacology, **45**, 673-683.

Powis, G. (1991) *Signal targets for anticancer drug development*. TIPS, 188-194.

Ramdas, L., Obeyesekere, N. U., McMurray, J. S., Gallick, G. E., Seifert, W. E. Jr. & Budde, R. J. (1995) *A tyrphostin-derived inhibitor of protein tyrosine kinases: isolation and characterization*. Archives of Biochemistry & Biophysics, **323**, 237-242.

Ramdas, L., McMurray, J. S. & Budde, R. J. (1994) *The degree of inhibition of protein tyrosine kinase activity by tyrphostin 23 and 25 is related to their instability*. Cancer Research, **54**, 867-869.

Rewcastle, G. W., Palmer, B. D., Thompson, A. M., Bridges, A. J., Cody, D. R., Zhou, H. Fry, D. W., McMichael, A. & Denny, W. A. (1996) *Tyrosine Kinase Inhibitors. 10. Isomeric 4-[(3-Bromophenyl)amino]pyrido[d]-pyrimidines Are Potent ATP Binding Site Inhibitors of the Tyrosine Kinase Function of the Epidermal Growth Factor Receptor*. J. Med. Chem., **39**, 1823-1835.

Rudd, C. E.; Janssen, O.; Prasad, K.V.S.; Raab, M.; da Silva, A.; Telfer, J.C.; Yamamoto, M. (1993) *src-related protein tyrosine kinases and their surface receptors*. Biochimica et Biophysica Acta, **1155**, 239-266.

Saperstein, R., Vicario, P. P., Strout, H. V., Brady, E., Slater, E. E., Greenlee, W. J., Ondeyka, D. L., Patchett, A. A. & Hangauer, D. G. (1989) *Design of a selective insulin receptor tyrosine kinase inhibitor and its effect on glucose uptake and metabolism in intact cells*. Biochemistry, **28**, 5694-5701.

Sawutz, D. G.; Bode, D. C.; Briggs, G. M.; Reid, J. R.; Canniff, P.; Caldwell, L.; Faltynek, C. R.; Miller, D.; Dunn, J. A.; Garavilla, L.; Guiles, J. W.; Weigelt, C.; Michne, W.; Treasurywala, A. M.; Silver, P. J. (1996) Biochem. Pharmacol. **51**, 1631.

Schwartzberg, P. L., et al. (1997) *Rescue of osteoclast function by transgenic expression of kinase-deficient Src in src-/- mutant mice*. Genes & Development **11**: 2835-2844.

Shiraishi, T., Owada, M. K., Tatsuka, M., Yamashita, T., Watanabe, K., Kakunaga, T. (1989) *Specific Inhibitors of Tyrosine-specific Protein Kinases: Properties of 4-hydroxycinnamamide derivatives in vitro*. Cancer Research, **49**, 2374-2378.

5

Showalter, H. H. & Kraker, A. J. (1997) *Small molecule inhibitors of the platelet-derived growth factor receptor, the fibroblast growth factor receptor, and src family tyrosine kinases*. Pharmacology & Therapeutics, **76**, 55-71.

10

Sicheri, F., Moarefi, I. & Kuriyan, J. (1997) *Crystal structure of the Src family tyrosine kinase Hck*. Nature, **385**, 602-609.

Skordalakes, E., Tyrell, R., Elgandy, S., Goodwin, C. A., Green, D., Dodson, G., Scully, M. F., Freyssinet, J-M. H., Kakkar, V. V., Deadman, J. J. (1997)

15

Crystallographic Structures of Human α -Thrombin Complexed to Peptide Boronic Acids Lacking a Positive Charge at P₁. Evidence of Novel Interactions. J. Am. Chem. Soc., **119**, 9935-9936.

Snyder, H. R., Kuck, J. A., Johnson, J. R. (1938) J. Am. Chem. Soc., **60**, 105.

20

Soloway, A. H., Whitman, B., Messer, J. R. (1962) J. Med. Pharm. Chem., **7**, 640.

Soloway, A. H., Whitman, B., Messer, J. R. (1960) J. Pharmacology and Experimental Therapeutics, **129**, 310-314.

25

Soloway, A. H. (1958) Science, **128**, 1572.

Songyang, Z., Blechner, S., Hoagland, N., Hoekstra, M. F., Piwnicka-Worms, H. & Cantley, L. C. (1994) *Use of an oriented peptide library to determine the optimal substrates of protein kinases*. Current Biology, **4**, 973-982.

30

Songyang, Z., Carraway III, K. L., Eck, M. J., Harrison, S. C., Feldman, R. A., Mohammadl, M., Schlessinger, J., Hubbard, S. R., Smith, D. P., Eng. C., Lorenzo, J.

- J., Ponder, B. A. J., Mayer, B. J. & Cantley, L. C. (1995) *Protein tyrosine kinases and SH2 domains have overlapping specificities*. Nature, **373**, 536-539.
- Staley, C. A.; Parikh, N. U.; Gallick, G. E. (1997) Cell Growth & Differentiation**
5 **8(3)**, 269.
- Stanwell, C., Burke, T. R. & Yuspa, S. H. (1995) Erbstatin Analogue Methyl 2,5-**
dihydrocinnamate Cross-links Proteins and is Cytotoxic to Normal and Neoplastic
Epithelial Cells by a Mechanism Independent of Tyrosine Kinase Inhibition. Cancer
10 Research, **55**, 4950-4956.
- Stanwell, C., Ye, B. & Burke, T. R. (1996) Cell Protein Cross-linking by Erbstatin**
and Related Compounds. Biochemical Pharmacology, **52**, 475-480.
- 15 **Takeshima, E.; Hamaguchi, M.; Watanbe, T.; Akiyama, S.; Kataoka, M.; Ohnishi,**
Y.; Xiao, H.; Hagai, Y., Taka, H. (1991) Aberrant elevation of tyrosine-specific
phosphorylation in human gastric cancer cells. Japan J. Cancer Res., **82**, 1428-1435.
- Talamonti, M.S.; Roh, M.S.; Curley, S.A.; Gallick, G.E. (1993) Increase in activity**
20 *and level of pp60^{c-src} in progressive stages of human colorectal cancer*. J. of Clinical
Investigation, **91**, 53-60.
- Taniyama, K., Fujiwara, H., Kuno, T., Saito, N., Shuntoh, H., Sakaue, M. (1989)**
Acute and subacute toxicity of 10B-paraboronophenylalanine. Pigment Cell
25 Research, **2**, 291-296.
- Taylor, S. J., Shalloway, D. (1996) Src and the control of cell division. Bioessays, **18**,
9-11.**
- 30 **Taylor, S. S., Knighton, D. R., Zheng, J., Sowadski, J. M., Gibbs, C. S. & Zoller, M.**
**J. (1993) A template for the protein kinase family. Trends in Biochemical Sciences,
18(3), 84-9.**

Taylor, S.S., Radzio-Andzelm, E. (1994) *Three protein kinase structures define a common motif. Structure, 2*, 345-355.

- 5 **Thakkar, K.,** Geahlen, R. L., Cushman, M. (1993) *Synthesis and protein-tyrosine kinase inhibitory activity of polyhydroxylated stilbene analogs of piceatannol. J. Med. Chem., 36*, 2950-2955.

- 10 **Weinberg, R. A.** (1989) *Oncogenes, antioncogenes, and the molecular basis of multistep carcinogenesis. Cancer Research, 49*, 3713-3721.

Wolfe, J. P., Ahman, J., Sadighi, J. P., Singer, R. A., Buchwald, S. L. (1997) *An ammonia equivalent for the palladium-catalyzed amination of aryl halides and triflates. Tet. Lett., 38*, 6367-6370.

- 15 **Wong, T.W. & Goldberg, A. R.** (1984) *Kinetics and mechanism of angiotensin phosphorylation by the transforming gene product of Rous Sarcoma Virus. J. Biol. Chem., 259*, 3127-3131.

- 20 **Xu, W.,** Harrison, S. C. & Eck, M. J. (1997) *Three-dimensional structure of the tyrosine kinase c-Src. Nature, 385*, 595-602.

Yamaguchi, H. & Hendrickson, W.A. (1996) *Structural basis for activation of human lymphocyte kinase Lck upon tyrosine phosphorylation. Nature, 384*, 484-489.

- 25 **Yamamoto, T.** (1993) *Molecular Basis of Cancer: Oncogenes and Tumor Suppressor Genes. Microbiol. Immunol. 37*, 11-22.

- 30 **Zheng, J.,** Knighton, D. R., Ten Eyck, L. R., Karlsson, R., Xuong, N-H., Taylor, S. S. & Sowadski, J. M. (1993) *Crystal structure of the catalytic subunit of cAMP-dependent protein kinase complexed with MgATP and peptide inhibitor. Biochemistry, 32*, 2154-61.

Zhanpeisov, N.U., Otsuka, K. (1992) *Cluster quantum chemical study of the mechanism of selective oxidation of ethane to acetaldehyde on boron-phosphorous mixed oxide catalysts*. React. Kinet. Catal. Lett., **48**, 301-308.

What is claimed:

1. A method for identifying inhibitors of protein kinases comprising:
providing a first module having a one or more functional groups for binding to
5 catalytic residues of the protein kinase;
combining the first module with a second module which provides a non-peptide scaffold; and
selecting combinations of the first and second modules which inhibit protein
kinase activity.
10
2. The method according to claim 1, wherein said providing a first
module comprises:
attaching the first module to a peptide scaffold;
identifying one or more functional groups which preferentially bind to
15 catalytic residues of the protein kinase; and wherein said combining the first module
with the second module comprises:
substituting the second module for the peptide scaffold.
3. The method according to claim 1, wherein the first module comprises a
20 functional group selected from the group consisting of boronic acid, a hydroxyl group,
phosphonic acid, sulfamic acid, a guanidino group, carboxylic acid, an aldehyde, an
amide, and hydroxymethylphosphonic acid.
4. The method according to claim 3, wherein the first module comprises
25 two or more functional groups.
5. The method according to claim 3, wherein the first module comprises a
boronic acid group.
- 30 6. The method according to claim 3, wherein the first module comprises a
hydroxyl group.

7. The method according to claim 3, wherein the first module comprises a
amide group.

8. The method according to claim 7, wherein the amide group is a vicinal
5 tricarbonyl amide.

9. The method according to claim 1, wherein the second module
comprises a group selected from the group consisting of indole, naphthalene,
biphenyl, isoquinoline, benzofuran, and benzothiophene .

10. The method according to claim 9, wherein the second module
comprises an indole.

11. The method according to claim 9, wherein the second module
15 comprises naphthalene.

12. The method according to claim 1, wherein more than one first module
is bound to the second module.

13. The method according to claim 1, wherein the first module further
comprises a linear chain comprising between one and three carbon atoms which links
the first module to the second module.

14. The method according to claim 13, wherein one of the carbon atoms in
25 the linear chain is substituted with a nitrogen, oxygen or sulfur atom.

15. The method according to claim 1, wherein the protein kinase is a
protein tyrosine kinase.

16. The method according to claim 15, wherein the protein tyrosine kinase
is selected from the group consisting of pp60^{c-src}, p56^{lck}, ZAP kinase, platelet derived
growth factor receptor tyrosine kinase, Bcr-Abl, VEGF receptor tyrosine kinase, and

epidermal growth factor receptor tyrosine kinase, and epidermal growth factor receptor-like tyrosine kinases.

17. The method according to claim 16, wherein the protein tyrosine kinase
5 is pp60^{c-src}.

18. The method according to claim 1, wherein the protein kinase is a protein serine kinase.

10 19. The method according to claim 15, wherein the protein serine kinase is selected from the group consisting of MAP kinase, protein kinase C, and CDK kinase.

20. The method according to claim 1, further comprising:
adding one or more specificity side chain elements to the combination of the
15 first and second modules.

21. A method for identifying improved protein kinase inhibitors,
comprising:
providing a first inhibitor produced according to the method of claim 1,
20 modifying the first module, specificity side chains, or a combination thereof of the first inhibitor; and
identifying modified inhibitors which have an increased ability to inhibit protein kinase activity when compared to the unmodified first inhibitor.

25 22. The method according to claim 1, wherein the protein kinase inhibitor inhibits protein kinase activity but does not inhibit ATP binding to the protein kinase.

23. A method for testing compounds for an ability to inhibit protein kinase activity comprising:
30 providing a protein kinase inhibitor according to the method of claim 1,
measuring the activity of the protein kinase in the presence of the inhibitor at the same temperature, pH, ionic strength, osmolarity, and free magnesium concentration as found in a cell which expresses the protein kinase; and

comparing the level of protein kinase activity to the level of activity from the protein kinase without the presence of the inhibitor.

24. A method of inhibiting a protein kinase comprising:

5 contacting the protein kinase with a compound comprising a first module having a functionality for binding to catalytic residues of the protein kinase and a second module which provides a non-peptide scaffold, wherein the combination of the first and second modules inhibits the protein kinase's activity.

10 25. The method according to claim 24, wherein the first module comprises a functional group selected from the group consisting of boronic acid, hydroxy, phosphonic acid, sulfamic acid, a guanidino group, carboxylic acid, an aldehyde, an amide, and hydroxymethylphosphonic acid.

15 26. The method according to claim 25, wherein the first module comprises a boronic acid group.

20 27. The method according to claim 25, wherein the first module comprises a hydroxyl group

28. The method according to claim 24, wherein the second module comprises a group selected from the group consisting of indole, naphthalene, biphenyl, isoquinoline, benzofuran, and benzothiophene .

25 29. The method according to claim 28, wherein the second module comprises an indole.

30 30. The method according to claim 28, wherein the second module comprises naphthalene.

31. The method according to claim 24, wherein more than one first module is bound to the second module.

32. The method according to claim 24, wherein a linear chain comprising between one and three carbon atoms links the first module to the second module.


33. The method according to claim 32, wherein one of the carbon atoms in the linear chain is substituted with a nitrogen, oxygen or sulfur atom.

34. The method according to claim 24, wherein the protein kinase is a protein tyrosine kinase.

35. The method according to claim 34, wherein the protein tyrosine kinase is selected from the group consisting of pp60^{c-src}, p56^{lck}, ZAP kinase, platelet derived growth factor receptor tyrosine kinase, Bcr-Abl, VEGF receptor tyrosine kinase, and epidermal growth factor receptor tyrosine kinase and epidermal growth factor receptor-like tyrosine kinases.


36. The method according to claim 34, wherein the protein tyrosine kinase is pp60^{c-src}.

37. The method according to claim 34, wherein the compound has the following formula:



wherein R1 is H or OH, R2 is H or OH, R3 is OH or H, and R4 is CH₃, CH₂(CH₃)R, or CH₂(CH₃)S, R5 is OCH₃, H, or OH, R6 is OCH₃, F, H, or OH, and R7 is OCH₃, H, OH, CO₂H, CO₂CH₃, CH₂CO₂H, or CH₂CO₂CH₃.


38. The method according to claim 34, wherein the compound has the following formula:



wherein R1 is OH or H, R2 is OH or H, R3 is OH or H, R4 is OH or H, R5 is OH, OMe, or H, R6 is OH, OMe, or H, R7 is OH, OMe, or H, and X is 0 or 1.

39. The method according to claim 34, wherein the compound has a specificity group which is an aliphatic amide.

40. The method according to claim 39, wherein the compound has the following structure:




41. The method according to claim 24, wherein the protein kinase is a protein serine kinase.

42. The method according to claim 41, wherein the protein serine kinase is selected from the group consisting of MAP kinase, protein kinase C, and CDK kinase.

43. The method according to claim 24, wherein the compound further comprises one or more specificity side chain elements attached to the combination of the first and second modules.

44. A non-peptide protein tyrosine kinase inhibitor having the formula:



wherein R1 is H or OH, R2 is H or OH, R3 is OH or H, and R4 is CH₃, CH₂(CH₃)R, or CH₂(CH₃)S, R5 is OCH₃, H, or OH, R6 is OCH₃, F, H, or OH, and R7 is OCH₃, H, OH, CO₂H, CO₂CH₃, CH₂CO₂H, or CH₂CO₂CH₃.


5

45. The non-peptide protein tyrosine kinase inhibitor according to claim 44, wherein the non-peptide protein tyrosine kinase inhibitor inhibits the activity of pp60^{c-src} tyrosine kinase.

10

46. A non-peptide protein tyrosine kinase inhibitor having the formula:

15



wherein R1 is OH or H, R2 is OH or H, R3 is OH or H, R4 is OH or H, R5 is OH, OMe, or H, R6 is OH, OMe, or H, R7 is OH, OMe, or H, and X is 0 or 1.

20


47. The non-peptide protein tyrosine kinase inhibitor according to claim 46, wherein R1 is OH, R2 is OH, R3 is H, R4 is H, R5 is OMe, R6 is H, R7 is H, and X is 1.

25

48. The non-peptide protein tyrosine kinase inhibitor according to claim 46, wherein the non-peptide protein tyrosine kinase inhibitor inhibits the activity of pp60^{c-src} tyrosine kinase.

30

49. A non-peptide protein tyrosine kinase inhibitor having the formula:



50. A method of treating a condition, responsive to a protein kinase inhibitor, in a patient comprising:

administering an effective dose of a protein kinase inhibitor to a patient wherein the protein kinase inhibitor comprises a first module having a functionality for binding to catalytic residues of the protein kinase and a second module which provides a non-peptide scaffold, wherein the combination of the first and second
5 modules inhibits protein kinase activity.

51. The method according to claim 50, wherein the condition is selected from the group consisting of cancer, psoriasis, atherosclerosis, or immune system activity.

52. The method according to claim 50, wherein the first module comprises a functional group selected from the group consisting of boronic acid, hydroxy, phosphonic acid, sulfamic acid, a guanidino group, carboxylic acid, an aldehyde, an amide, and hydroxymethylphosphonic acid.

53. The method according to claim 52, wherein the first module comprises a boronic acid group.

54. The method according to claim 52, wherein the first module comprises
20 a hydroxyl group

55. The method according to claim 50, wherein the second module comprises a group selected from the group consisting of indole, naphthalene, biphenyl, isoquinoline, benzofuran, and benzothiophene .

56. The method according to claim 55, wherein the second module comprises indole.

57. The method according to claim 55, wherein the second module
30 comprises naphthalene.

58. The method according to claim 50, wherein more than one first module is bound to the second module.

59. The method according to claim 50, wherein a linear chain comprising between one and three carbon atoms links the first module to the second module.


60. The method according to claim 59, wherein one of the carbon atoms in the linear chain is substituted with a nitrogen, oxygen or sulfur atom.

61. The method according to claim 50, wherein the protein kinase is a protein tyrosine kinase.

62. The method according to claim 61, wherein the protein tyrosine kinase is selected from the group consisting of pp60^{c-src}, p56^{lck}, ZAP kinase, platelet derived growth factor receptor tyrosine kinase, Bcr-Abl, VEGF receptor tyrosine kinase, and epidermal growth factor receptor tyrosine kinase, and epidermal growth factor receptor-like tyrosine kinases.


63. The method according to claim 62, wherein the protein tyrosine kinase is pp60^{c-src}.

64. The method according to claim 63, wherein the compound has the following formula:




wherein R1 is H or OH, R2 is H or OH, R3 is OH or H, and R4 is CH₃, CH₂(CH₃)R, or CH₂(CH₃)S, R5 is OCH₃, H, or OH, R6 is OCH₃, F, H, or OH, and R7 is OCH₃, H, OH, CO₂H, CO₂CH₃, CH₂CO₂H, or CH₂CO₂CH₃.

65. The method according to claim 63, wherein the compound has the following formula:



wherein R₁ is OH or H, R₂ is OH or H, R₃ is OH or H, R₄ is OH or H, R₅ is OH, OMe, or H, R₆ is OH, OMe, or H, R₇ is OH, OMe, or H, and X is 0 or 1.

66. The method according to claim 63, wherein the compound has the following formula:



67. The method according to claim 50, wherein the protein kinase is a protein serine kinase.


68. The method according to claim 67, wherein the protein serine kinase is selected from the group consisting of MAP kinase, protein kinase C, and CDK kinase.

69. The method according to claim 50, wherein the compound further comprises one or more specificity side chain elements attached to the combination of the first and second modules.

The present invention provides a method for identifying inhibitors of protein kinases. Methods are also provided for inhibiting protein kinase activity. Specific non-peptide protein tyrosine kinase inhibitors are provided. The protein kinases produced using the method of the present invention may be used to treat a number of conditions in patients, including cancer, psoriasis, atherosclerosis, or immune system activity.

Figure 1

MODULAR STRATEGY FOR DEVELOPING NON-PEPTIDE PROTEIN KINASE INHIBITORS



KEY

M₁ = Module consisting of a selection of validated functionalities for binding to the conserved catalytic residues.
M₂ = Module consisting of a selection of non-peptide scaffolds for PTK's.
S_n = Specificity elements.

Figure 3

General Module M₁ Design Features For Binding To The Conserved Protein Kinase Catalytic Region




Figure 4
SUBSTRATE BEHAVIOR FOR BORONIC ACID PKA INHIBITORS 21 & 22





Figure 5

Binding interactions of src substrate
Ac-Ile-Tyr-Gly-Glu-Phe-NH₂ in model src active site.




Figure 6

Design of naphthalene-based src inhibitor scaffold






Table 1. Continued	
Parameter	Value
α	0.05
β	0.05
γ	0.05
δ	0.05
ϵ	0.05
ζ	0.05
η	0.05
θ	0.05
ι	0.05
κ	0.05
λ	0.05
μ	0.05
ν	0.05
ξ	0.05
\omicron	0.05
π	0.05
ρ	0.05
σ	0.05
τ	0.05
υ	0.05
ϕ	0.05
χ	0.05
ψ	0.05
ω	0.05
κ	0.05
λ	0.05
μ	0.05
ν	0.05
ξ	0.05
\omicron	0.05
π	0.05
ρ	0.05
σ	0.05
τ	0.05
υ	0.05
ϕ	0.05
χ	0.05
ψ	0.05
ω	0.05
κ	0.05
λ	0.05
μ	0.05
ν	0.05
ξ	0.05
\omicron	0.05
π	0.05
ρ	0.05
σ	0.05
τ	0.05
υ	0.05
ϕ	0.05
χ	0.05
ψ	0.05
ω	0.05
κ	0.05
λ	0.05
μ	0.05
ν	0.05
ξ	0.05
\omicron	0.05
π	0.05
ρ	0.05
σ	0.05
τ	0.05
υ	0.05
ϕ	0.05
χ	0.05
ψ	0.05
ω	0.05
κ	0.05
λ	0.05
μ	0.05
ν	0.05
ξ	0.05
\omicron	0.05
π	0.05
ρ	0.05
σ	0.05
τ	0.05
υ	0.05
ϕ	0.05
χ	0.05
ψ	0.05
ω	0.05
κ	0.05
λ	0.05
μ	0.05
ν	0.05
ξ	0.05
\omicron	0.05
π	0.05
ρ	0.05
σ	0.05
τ	0.05
υ	0.05
ϕ	0.05
χ	0.05
ψ	0.05
ω	0.05
κ	0.05
λ	0.05
μ	0.05
ν	0.05
ξ	0.05
\omicron	0.05
π	0.05
ρ	0.05
σ	0.05
τ	0.05
υ	0.05
ϕ	0.05
χ	0.05
ψ	0.05
ω	0.05
κ	0.05
λ	0.05
μ	0.05
ν	0.05
ξ	0.05
\omicron	0.05
π	0.05
ρ	0.05
σ	0.05
τ	0.05
υ	0.05
ϕ	0.05
χ	0.05
ψ	0.05
ω	0.05
κ	0.05
λ	0.05
μ	0.05
ν	0.05
ξ	0.05
\omicron	0.05
π	0.05
ρ	0.05
σ	0.05
τ	0.05
υ	0.05
ϕ	0.05
χ	0.05
ψ	0.05

Design of isoquinoline and indole-based src inhibitor scaffolds




**src:isoquinoline-based
non-peptide inhibitor
binding mode**



**src:indole-based
non-peptide inhibitor
binding mode**

Figure 8



Parameter	Estimated value	Standard error
α_0	0.0	0.0
α_1	0.0	0.0
α_2	0.0	0.0
α_3	0.0	0.0
α_4	0.0	0.0
α_5	0.0	0.0
α_6	0.0	0.0
α_7	0.0	0.0
α_8	0.0	0.0
α_9	0.0	0.0
α_{10}	0.0	0.0
α_{11}	0.0	0.0
α_{12}	0.0	0.0
α_{13}	0.0	0.0
α_{14}	0.0	0.0
α_{15}	0.0	0.0
α_{16}	0.0	0.0
α_{17}	0.0	0.0
α_{18}	0.0	0.0
α_{19}	0.0	0.0
α_{20}	0.0	0.0
α_{21}	0.0	0.0
α_{22}	0.0	0.0
α_{23}	0.0	0.0
α_{24}	0.0	0.0
α_{25}	0.0	0.0
α_{26}	0.0	0.0
α_{27}	0.0	0.0
α_{28}	0.0	0.0
α_{29}	0.0	0.0
α_{30}	0.0	0.0
α_{31}	0.0	0.0
α_{32}	0.0	0.0
α_{33}	0.0	0.0
α_{34}	0.0	0.0
α_{35}	0.0	0.0
α_{36}	0.0	0.0
α_{37}	0.0	0.0
α_{38}	0.0	0.0
α_{39}	0.0	0.0
α_{40}	0.0	0.0
α_{41}	0.0	0.0
α_{42}	0.0	0.0
α_{43}	0.0	0.0
α_{44}	0.0	0.0
α_{45}	0.0	0.0
α_{46}	0.0	0.0
α_{47}	0.0	0.0
α_{48}	0.0	0.0
α_{49}	0.0	0.0
α_{50}	0.0	0.0
α_{51}	0.0	0.0
α_{52}	0.0	0.0
α_{53}	0.0	0.0
α_{54}	0.0	0.0
α_{55}	0.0	0.0
α_{56}	0.0	0.0
α_{57}	0.0	0.0
α_{58}	0.0	0.0
α_{59}	0.0	0.0
α_{60}	0.0	0.0
α_{61}	0.0	0.0
α_{62}	0.0	0.0
α_{63}	0.0	0.0
α_{64}	0.0	0.0
α_{65}	0.0	0.0
α_{66}	0.0	0.0
α_{67}	0.0	0.0
α_{68}	0.0	0.0
α_{69}	0.0	0.0
α_{70}	0.0	0.0
α_{71}	0.0	0.0
α_{72}	0.0	0.0
α_{73}	0.0	0.0
α_{74}	0.0	0.0
α_{75}	0.0	0.0
α_{76}	0.0	0.0
α_{77}	0.0	0.0
α_{78}	0.0	0.0
α_{79}	0.0	0.0
α_{80}	0.0	0.0
α_{81}	0.0	0.0
α_{82}	0.0	0.0
α_{83}	0.0	0.0
α_{84}	0.0	0.0
α_{85}	0.0	0.0
α_{86}	0.0	0.0
α_{87}	0.0	0.0
α_{88}	0.0	0.0
α_{89}	0.0	0.0
α_{90}	0.0	0.0
α_{91}	0.0	0.0
α_{92}	0.0	0.0
α_{93}	0.0	0.0
α_{94}	0.0	0.0
α_{95}	0.0	0.0
α_{96}	0.0	0.0
α_{97}	0.0	0.0
α_{98}	0.0	0.0
α_{99}	0.0	0.0
α_{100}	0.0	0.0




Figure 10




Figure 11




Figure 11




Figure 13

(Residues are from the IRTK ternary structure and dotted bonds are H-bonds)




FIGURE 14




FIGURE 15A

Ovarian Tumor N015 Sensitivity To Drugs:
Suspended Cell Culture




FIGURE 15B

Normal Human Fibroblasts Sensitivity To
Src Inhibitors: Subconfluent Cell Culture





FIGURE 15C



COMBINED DECLARATION FOR PATENT
APPLICATION AND POWER OF ATTORNEY
(Includes Reference to PCT International Applications)

ATTORNEY'S DOCKET NUMBER
19226/931 (R-5495)

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

A NOVEL METHOD FOR DESIGNING PROTEIN KINASE INHIBITORS

the specification of which (check only one item below):

☒ is attached hereto.

☐ was filed as U.S. Patent Application Serial No. _____ on _____ and was amended on _____ (if applicable).

☐ was filed as PCT International Application Number _____ on _____ and was amended under PCT Article 19 on _____ (if applicable).

I hereby state that I have reviewed and understand the contents of the above-identified specifications, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the patentability of this application in accordance with Title 37, Code of Federal Regulations, § 1.56(a).

I hereby claim foreign priority benefits under Title 35, United States Code, § 119 of any foreign application(s) for patent or inventor's certificate or of any PCT international application(s) designating at least one country other than the United States listed below and have also identified below any foreign application(s) for patent or inventor's certificate or any PCT international application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) of which priority is claimed:

PRIOR FOREIGN/PCT APPLICATION(S) AND ANY PRIORITY CLAIMS UNDER 35 U.S.C. 119:

COUNTRY (IF PCT, indicate "PCT")	APPLICATION NUMBER	DATE OF FILING (day, month, year)	PRIORITY CLAIMED UNDER 35 USC 119
United States	60/115,643	13 Jan 1999	<input type="checkbox"/> YES <input type="checkbox"/> NO
			<input type="checkbox"/> YES <input type="checkbox"/> NO
			<input type="checkbox"/> YES <input type="checkbox"/> NO
			<input type="checkbox"/> YES <input type="checkbox"/> NO
			<input type="checkbox"/> YES <input type="checkbox"/> NO
			<input type="checkbox"/> YES <input type="checkbox"/> NO
			<input type="checkbox"/> YES <input type="checkbox"/> NO
			<input type="checkbox"/> YES <input type="checkbox"/> NO

COMBINED DECLARATION FOR PATENT
APPLICATION AND POWER OF ATTORNEY (Continued)
(Includes Reference to PCT International Applications)

ATTORNEY'S DOCKET NUMBER
19226/931 (R-5495)

I hereby claim the benefit under Title 35, United States Code, § 120 of any United States application(s) or PCT international application(s) designating the United States of America that is/are listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in that/those prior application(s) in the manner provided by the first paragraph of Title 35, United States Code, § 112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, § 1.56(a) which occurred between the filing date of the prior application(s) and the national or PCT International filing date of this application:

PRIOR U.S. APPLICATIONS OR PCT INTERNATIONAL APPLICATIONS DESIGNATING THE U.S. FOR BENEFIT UNDER 35 U.S.C. 120:

U.S. APPLICATIONS

STATUS (Check One)

U.S. APPLICATION NUMBER

U.S. FILING DATE

PATENTED

PENDING

ABANDONED

PCT APPLICATIONS DESIGNATING THE U.S.

PCT
APPLICATION NO.

PCT
FILING DATE

U.S. SERIAL NUMBERS
ASSIGNED (if any)

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith. **Michael L. Goldman, Registration No. 30,727; Gunnar G. Leinberg, Registration No. 35,584; Dennis M. Connolly, Registration No. 40,964; Edwin V. Merkel, Registration No. 40,087; Georgia Caton, Registration No. 44,597; Grant E. Pollack, Registration No. 34,097**

Send Correspondence to:

**Michael L. Goldman
NIXON PEABODY LLP
Clinton Square, P.O. Box 1051
Rochester, New York 14603**

Direct telephone calls to:

**Michael L. Goldman
(716) 263-1304**

FULL NAME
OF INVENTOR

FAMILY NAME
Hangauer, Jr.

FIRST GIVEN NAME
David

SECOND GIVEN NAME
G.

RESIDENCE &
CITIZENSHIP

CITY
East Amherst

STATE/FOREIGN COUNTRY
New York

COUNTRY OF CITIZENSHIP
United States

POST OFFICE
ADDRESS

P.O. ADDRESS
8431 Hidden Oak Drive

CITY
East Amherst

STATE & ZIP CODE/COUNTRY
New York 14051/USA

FULL NAME OF
INVENTOR

FAMILY NAME
Marsilje

FIRST GIVEN NAME
Thomas

SECOND GIVEN NAME
H.

RESIDENCE &
CITIZENSHIP

CITY
Buffalo

STATE/FOREIGN COUNTRY
New York

COUNTRY OF CITIZENSHIP
United States

POST OFFICE
ADDRESS

P.O. ADDRESS
84 Tracey Street

CITY
Buffalo

STATE & ZIP CODE/COUNTRY
New York 14201/USA

FULL NAME OF
INVENTOR

FAMILY NAME
Milkiewicz

FIRST GIVEN NAME
Karen

SECOND GIVEN NAME
L.

RESIDENCE &
CITIZENSHIP

CITY
Buffalo

STATE/FOREIGN COUNTRY
New York

COUNTRY OF CITIZENSHIP
United States

POST OFFICE
ADDRESS

P.O. ADDRESS
665 Kenmore Avenue

CITY
Buffalo

STATE & ZIP CODE/COUNTRY
New York 14223/USA

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

SIGNATURE OF INVENTOR 201

SIGNATURE OF INVENTOR 202

SIGNATURE OF INVENTOR 203

UNSIGNED

UNSIGNED

UNSIGNED

DATE

DATE

DATE

EXPRESS MAIL CERTIFICATE

DOCKET NO. : 19226/931 (R-5495)

APPLICANT(S) : David G. Hangauer, Jr., Thomas H. Marsilje,
and Karen L. Milkiewicz

TITLE : A NOVEL METHOD FOR DESIGNING PROTEIN KINASE
INHIBITORS

Certificate is attached to the **Utility Patent Application Transmittal Form**
(2 pages) (in duplicate) of the above-named application.


“EXPRESS MAIL” NUMBER: EL434571572US

DATE OF DEPOSIT: January 13, 2000

I hereby certify that this paper or fee is being deposited with the United States
Postal Service “Express Mail Post Office to Addressee” service under 37 CFR 1.10 on the
date indicated above and is addressed to the Assistant Commissioner for Patents,
Washington, D.C. 20231, **Box Patent Application**.

Jo Ann Whalen

(Typed or printed name of person mailing
paper or fee)



(Signature of person mailing paper or fee)